Single domain serum albumin binding proteins

By designing specific single domain serum albumin-binding proteins, including specific CDR sequences and undergoing amino acid replacement, the problem of prolonging the half-life of albumin carriers and insufficient binding affinity in the prior art is solved, and efficient stability in the human body and Pharmacokinetic improvement.

CN119060177APending Publication Date: 2024-12-03HARPOON THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410731815.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2016-05-20
Filing Date
2017-05-19
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The prior art is difficult to effectively prolong the half-life of therapeutic molecules, especially when using albumin as a carrier, there is a problem of insufficient binding affinity and stability.

Method used

A single domain serum albumin-binding protein was developed, containing specific complementary determining regions CDR1, CDR2 and CDR3 amino acid sequences, which achieved prolonged elimination half-life through binding to human, cynomolgus monkeys and mouse serum albumin, and Amino acid substitution is performed at CDR1, CDR2 or CDR3 to optimize binding affinity and stability.

Benefits of technology

It achieves prolonging the half-life of therapeutic molecules in the human body, improving the stability and efficiency of the drug, reducing side effects, and its binding affinity is in the range of 1nM to 100nM, suitable for a variety of serum albumin, significantly improving pharmacokinetic parameters .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119060177A_ABST
    Figure CN119060177A_ABST
Patent Text Reader

Abstract

Disclosed herein are single domain serum albumin binding proteins having improved thermal stability, binding affinity, and robust aggregation properties. Also described herein are multispecific binding proteins comprising single domain serum albumin binding proteins according to the present disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The application is a divisional application of the Chinese patent application with the application date of May 19, 2017, application number 201780045208.7, and invention name “Single Domain Serum Albumin Binding Protein” (the corresponding PCT application with the application date of May 19, 2017 and application number (PCT / US2017 / 033665)).

[0002] Cross-references

[0003] This application claims the benefit of U.S. Provisional Application No. 62 / 339,682, filed May 20, 2016, which is incorporated herein by reference in its entirety.

[0004] Sequence Listing

[0005] This application contains a sequence listing, which has been submitted electronically in ASCII format and is incorporated herein by reference in its entirety. The ASCII copy was created on May 18, 2017, is named 47517-703_601_SEQ.txt, and is 22,218 bytes in size.

[0006] Incorporation by reference

[0007] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference and was set forth in its entirety herein. Background Art

[0008] Albumin is the most abundant plasma protein that is highly soluble, very stable, and has an extremely long circulating half-life. Albumin can be used in a variety of ways to extend the circulating half-life of therapeutic molecules. The present disclosure provides single domain albumin binding proteins that can be used to extend the half-life of therapeutic molecules. Summary of the invention

[0009] In one embodiment, the present invention provides a single domain serum albumin binding protein comprising complementarity determining regions CDR1, CDR2 and CDR3, wherein (a) the amino acid sequence of CDR1 is as shown in GFX1X2X3X4FGMS (SEQ ID NO.1), X1 is threonine, arginine, lysine, serine or proline, X2 is phenylalanine or tyrosine, X3 is serine, arginine or lysine, and X4 is serine, lysine, arginine or alanine; (b) the amino acid sequence of CDR2 is as shown in SISGSGX5X6TLYAX7SX8K (SEQ ID NO.2), X5 is serine, arginine, threonine or alanine, X6 is aspartic acid, histidine, valine or threonine, X7 is aspartic acid, histidine, arginine or serine, and X8 is valine or leucine; and (c) the amino acid sequence of CDR3 is as shown in GGSLX9X 10 (SEQ ID NO.3), X9 is serine, arginine, threonine or lysine, and X 10 is arginine, lysine, valine, proline or asparagine, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9 and X 10are not threonine, phenylalanine, serine, serine, serine, aspartic acid, aspartic acid, valine, serine and arginine at the same time. In some embodiments, the single domain serum albumin binding protein comprises the following formula: f1-r1-f2-r2-f3-r3-f4, wherein r1 is SEQ ID NO.1; r2 is SEQ ID NO.2, and r3 is SEQ ID NO.3; and wherein f1, f2, f3 and f4 are selected framework residues such that the protein is at least 80% identical to the amino acid sequence shown in SEQ ID NO.10. In some embodiments, the single domain serum albumin binding protein comprises such an amino acid sequence, wherein r1 comprises SEQ ID NO.14, SEQ ID NO.15 or SEQ ID NO.16. In some embodiments, the single domain serum albumin binding protein comprises an amino acid sequence wherein r2 comprises SEQ ID NO.17, SEQ ID NO.18, SEQ ID NO.19, SEQ ID NO.20, SEQ ID NO.21, or SEQ ID NO.22. In some embodiments, the single domain serum albumin binding protein comprises an amino acid sequence wherein r3 comprises SEQ ID NO.23 or SEQ ID NO.24. In some embodiments, the single domain serum albumin binding protein comprises an amino acid sequence wherein r1 comprises SEQ ID NO.14. In some embodiments, the single domain serum albumin binding protein comprises an amino acid sequence wherein r1 comprises SEQ ID NO.15, r2 comprises SEQ ID NO.17, and r3 comprises SEQ ID NO.23. In some embodiments, the single domain serum albumin binding protein comprises an amino acid sequence wherein r1 comprises SEQ ID NO.16, and r3 comprises SEQ ID NO.23. In some embodiments, the single domain serum albumin binding protein comprises an amino acid sequence wherein r1 comprises SEQ ID NO. 15, and r2 comprises SEQ ID NO. 18. In some embodiments, the single domain serum albumin binding protein comprises an amino acid sequence wherein r1 comprises SEQ ID NO. 14, and r3 comprises SEQ ID NO. 23. In some embodiments, the single domain serum albumin binding protein comprises an amino acid sequence wherein r1 comprises SEQ ID NO. 15, r2 comprises SEQ ID NO. 19, and r3 comprises SEQ ID NO. 24.In some embodiments, the single domain serum albumin binding protein comprises an amino acid sequence wherein r1 comprises SEQ ID NO.14 and r2 comprises SEQ ID NO.20. In some embodiments, the single domain serum albumin binding protein comprises an amino acid sequence wherein r1 comprises SEQ ID NO.15 and r2 comprises SEQ ID NO.21. In some embodiments, the single domain serum albumin binding protein comprises an amino acid sequence wherein r1 comprises SEQ ID NO.15, r2 comprises SEQ ID NO.22, and r3 comprises SEQ ID NO.24. In some embodiments, the single domain serum albumin binding protein has an amino acid sequence selected from the group consisting of SEQ ID NO.4, SEQ ID NO.5, SEQ ID NO.6, SEQ ID NO.7, SEQ ID NO.8, SEQ ID NO.9, SEQ ID NO.25, SEQ ID NO.26, and SEQ ID NO.27. In some embodiments, the single domain serum albumin binding protein comprises an amino acid sequence as shown in SEQ ID NO.4. In some embodiments, the single domain serum albumin binding protein comprises the amino acid sequence shown in SEQ ID NO.7. In some embodiments, the single domain serum albumin binding protein comprises the amino acid sequence shown in SEQ ID NO.9. In some embodiments, the single domain serum albumin binding protein comprises the amino acid sequence shown in SEQ ID NO.26. In some embodiments, the single domain serum albumin binding protein comprises the amino acid sequence shown in SEQ ID NO.27. In some embodiments, the single domain serum albumin binding protein comprises the amino acid sequence shown in SEQ ID NO.5. In some embodiments, the single domain serum albumin binding protein comprises the amino acid sequence shown in SEQ ID NO.6. In some embodiments, the single domain serum albumin binding protein comprises the amino acid sequence shown in SEQ ID NO.8. In some embodiments, the single domain serum albumin binding protein comprises the amino acid sequence shown in SEQ ID NO.25.

[0010] In some embodiments, the single domain serum albumin binding protein binds to a serum albumin selected from human serum albumin, cynomolgus monkey serum albumin, and mouse serum albumin. In some embodiments, the single domain serum albumin binding protein binds to human serum albumin and cynomolgus monkey serum albumin with comparable binding affinity (Kd). In some embodiments, the binding affinity (Kd) of the single domain serum albumin binding protein to mouse serum albumin is about 1.5 times to about 20 times weaker than the binding affinity (Kd) of the protein to human and cynomolgus monkey serum albumin. In some embodiments, the single domain serum albumin binding protein binds to human serum albumin with a human Kd (hKd) of about 1 nM to about 100 nM, and binds to cynomolgus monkey serum albumin with a cynomolgus monkey Kd (cKd) of 1 nM to 100 nM. In some embodiments, the hKd and cKd of the single domain serum albumin binding protein are 1 nM to about 5 nM or about 5 nM to about 10 nM. In some embodiments, the single domain serum albumin binding protein has an hKd and cKd of about 1 nM to about 2 nM, about 2 nM to about 3 nM, about 3 nM to about 4 nM, about 4 nM to about 5 nM, about 5 nM to about 6 nM, about 6 nM to about 7 nM, about 7 nM to about 8 nM, about 8 nM to about 9 nM, or about 9 nM to about 10 nM. In some embodiments, the single domain serum albumin binding protein has a ratio of hKd to cKd (hKd:cKd) in the range of about 20:1 to about 1:2.

[0011] In some embodiments, the single domain serum albumin binding protein comprises the amino acid sequence as shown in SEQ ID NO.4, and wherein the hKd and the cKd are about 1 nM to about 5 nM. In some embodiments, the single domain serum albumin binding protein comprises the amino acid sequence as shown in SEQ ID NO.5, and wherein the hKd and the cKd are about 1 nM to about 5 nM. In some embodiments, the single domain serum albumin binding protein comprises the amino acid sequence as shown in SEQ ID NO.6, and wherein the hKd and the cKd are about 1 nM to about 5 nM. In some embodiments, the single domain serum albumin binding protein comprises the amino acid sequence as shown in SEQ ID NO.7, and wherein the hKd and the cKd are about 1 nM to about 5 nM. In some embodiments, the single domain serum albumin binding protein comprises the amino acid sequence as shown in SEQ ID NO.8, and wherein the hKd and the cKd are about 5 nM to about 10 nM. In some embodiments, the single domain serum albumin binding protein comprises the amino acid sequence as shown in SEQ ID NO.9, and wherein the hKd and the cKd are about 1 nM to about 5 nM. In some embodiments, the single domain serum albumin binding protein comprises the amino acid sequence as shown in SEQ ID NO.22, and wherein the hKd and the cKd are about 1 nM to about 5 nM. In some embodiments, the single domain serum albumin binding protein comprises the amino acid sequence as shown in SEQ ID NO.23, and wherein the hKd and the cKd are about 1 nM to about 5 nM. In some embodiments, the single domain serum albumin binding protein comprises the amino acid sequence as shown in SEQ ID NO.24, and wherein the hKd and the cKd are about 1 nM to about 5 nM.

[0012] In some embodiments, the single domain serum albumin binding protein has an elimination half-life of at least 12 hours, at least 20 hours, at least 25 hours, at least 30 hours, at least 35 hours, at least 40 hours, at least 45 hours, at least 50 hours, or at least 100 hours.

[0013] In another embodiment, a single domain serum albumin binding protein comprising CDR1, CDR2 and CDR3 is provided, which comprises the sequence as shown in SEQ ID NO.10, wherein one or more amino acid residues selected from amino acid positions 28, 29, 30 or 31 of CDR1, positions 56, 57, 62 or 64 of CDR2, and positions 103 and 104 of CDR3 are substituted, wherein amino acid position 28 is substituted with arginine, lysine, serine or proline, amino acid position 29 is substituted with tyrosine, amino acid position 30 is substituted with arginine or lysine, amino acid position 31 is substituted with lysine, arginine or alanine, amino acid position 56 is substituted with arginine, threonine or alanine, amino acid position 57 is substituted with histidine, valine or threonine, amino acid position 62 is substituted with histidine, arginine, glutamic acid or serine, amino acid position 64 is substituted with leucine, amino acid position 103 is substituted with arginine, threonine or lysine, and amino acid position 104 is substituted with lysine, valine, proline or asparagine. In some embodiments, the single domain serum albumin binding protein comprises one or more additional substitutions at amino acid positions other than positions 28, 29, 30, 31, 56, 57, 62, 64, 103, and 104. In some embodiments, the single domain serum albumin binding protein comprises a substitution at position 29. In some embodiments, the single domain serum albumin binding protein comprises a substitution at position 31. In some embodiments, the single domain serum albumin binding protein comprises a substitution at position 56. In some embodiments, the single domain serum albumin binding protein comprises a substitution at position 62. In some embodiments, the single domain serum albumin binding protein comprises a substitution at position 64. In some embodiments, the single domain serum albumin binding protein comprises a substitution at position 104. In some embodiments, the single domain serum albumin binding protein comprises a substitution at amino acid positions 31 and 62. In some embodiments, the single domain serum albumin binding protein comprises an amino acid sequence wherein position 31 is substituted with arginine. In some embodiments, the single domain serum albumin binding protein comprises an amino acid sequence wherein position 31 is substituted with arginine and amino acid position 62 is substituted with glutamic acid. In some embodiments, the single domain serum albumin binding protein comprises substitutions at amino acid positions 31, 56, 64 and 104. In some embodiments, the single domain serum albumin binding protein comprises an amino acid sequence wherein position 31 is substituted with lysine, amino acid position 56 is substituted with alanine, amino acid position 64 is substituted with leucine, and amino acid position 104 is substituted with lysine. In some embodiments, the single domain serum albumin binding protein comprises substitutions at amino acid positions 29 and 104.In some embodiments, the single domain serum albumin binding protein comprises an amino acid sequence wherein amino acid position 29 is substituted with tyrosine and amino acid position 104 is substituted with lysine. In some embodiments, the single domain serum albumin binding protein comprises substitutions at amino acid positions 31 and 56. In some embodiments, the single domain serum albumin binding protein comprises an amino acid sequence wherein amino acid position 31 is substituted with lysine and amino acid position 56 is substituted with threonine. In some embodiments, the single domain serum albumin binding protein comprises substitutions at amino acid positions 31, 56 and 62. In some embodiments, the single domain serum albumin binding protein comprises an amino acid sequence wherein amino acid position 31 is substituted with lysine, amino acid position 56 is substituted with threonine, and amino acid position 62 is substituted with glutamic acid. In some embodiments, the single domain serum albumin binding protein comprises substitutions at amino acid positions 31 and 104. In some embodiments, the single domain serum albumin binding protein comprises an amino acid sequence wherein amino acid position 31 is substituted with arginine and amino acid position 104 is substituted with lysine. In some embodiments, the single domain serum albumin binding protein comprises a substitution at amino acid positions 31, 56, and 104. In some embodiments, the single domain serum albumin binding protein comprises an amino acid sequence wherein amino acid position 31 is substituted with lysine, amino acid position 56 is substituted with arginine, and amino acid position 104 is substituted with valine. In some embodiments, the single domain serum albumin binding protein comprises a substitution at amino acid positions 31, 56, 62, and 104. In some embodiments, the single domain serum albumin binding protein comprises an amino acid sequence wherein amino acid position 31 is substituted with lysine, amino acid position 56 is substituted with arginine, amino acid position 62 is substituted with glutamic acid, and amino acid position 104 is substituted with valine. In some embodiments, the single domain serum albumin binding protein comprises an amino acid sequence wherein amino acid position 31 is substituted with arginine, and the single domain serum albumin binding protein has an hKd and cKd of about 1 nM to about 5 nM. In some embodiments, the single domain serum albumin binding protein comprises an amino acid sequence wherein amino acid position 31 is substituted with arginine and amino acid position 62 is substituted with glutamic acid, and the single domain serum albumin binding protein has an hKd and a cKd of about 1 nM to about 5 nM.In some embodiments, the single domain serum albumin binding protein comprises an amino acid sequence wherein amino acid position 31 is substituted with lysine, amino acid position 56 is substituted with alanine, amino acid position 64 is substituted with leucine, and amino acid position 104 is substituted with lysine, and wherein the hKd and cKd of the single domain serum albumin binding protein are from about 1 nM to about 5 nM. In some embodiments, the single domain serum albumin binding protein comprises an amino acid sequence wherein amino acid position 29 is substituted with tyrosine, amino acid position 104 is substituted with lysine, and wherein the hKd and cKd are from about 1 nM to about 5 nM. In some embodiments, the single domain serum albumin binding protein comprises an amino acid sequence wherein amino acid position 31 is substituted with lysine, amino acid position 56 is substituted with threonine, and wherein the hKd and cKd of the single domain serum albumin binding protein are from about 1 nM to about 5 nM. In some embodiments, the single domain serum albumin binding protein comprises an amino acid sequence wherein amino acid position 31 is substituted with lysine, amino acid position 56 is substituted with threonine, and amino acid position 62 is substituted with glutamic acid, and wherein the hKd and the cKd are from about 1 nM to about 5 nM. In some embodiments, the single domain serum albumin binding protein comprises an amino acid sequence wherein amino acid position 31 is substituted with arginine, amino acid position 104 is substituted with lysine, and wherein the hKd and cKd of the single domain serum albumin binding protein are from about 5 nM to about 10 nM. In some embodiments, the single domain serum albumin binding protein comprises an amino acid sequence wherein amino acid position 31 is substituted with lysine, amino acid position 56 is substituted with arginine, amino acid position 104 is substituted with valine, and wherein the hKd and cKd of the single domain serum albumin binding protein are from about 1 nM to about 5 nM. In some embodiments, the single domain serum albumin binding protein comprises an amino acid sequence wherein amino acid position 31 is substituted with lysine, amino acid position 56 is substituted with arginine, amino acid position 62 is substituted with glutamic acid, and amino acid position 104 is substituted with valine, and wherein the single domain serum albumin binding protein has an hKd and a cKd of about 1 nM to about 5 nM.

[0014] In another embodiment, provided herein is a single domain serum albumin binding protein comprising at least one mutation at CDR1, CDR2 or CDR3, wherein CDR1 comprises the sequence as set forth in SEQ ID NO: 11, CDR2 comprises the sequence as set forth in SEQ ID NO: 12, and CDR3 comprises the sequence as set forth in SEQ ID NO. 13, and wherein the at least one mutation is not at amino acid position 1, 2, 7, 8, 9 or 10 of SEQ ID NO: 11, position 1, 3, 6, 10 or 11 of SEQ ID NO: 12, or position 1 or 2 of SEQ ID NO: 13. In some embodiments, the single domain serum albumin binding protein comprises at least one mutation at an amino acid position selected from positions 3, 4, 5 and 6 of CDR1 (SEQ ID NO: 11), amino acid positions 7, 8, 13 and 15 of CDR2 (SEQ ID NO: 12), and amino acid positions 5 and 6 of CDR3 (SEQ ID NO: 13). In some embodiments, the single domain serum albumin binding protein comprises one or more additional substitutions at amino acid positions other than 3, 4, 5, and 6 of CDR1 (SEQ ID NO: 11), amino acid positions 7, 8, 13, and 15 of CDR2 (SEQ ID NO: 12), and amino acid positions 5 and 6 of CDR3 (SEQ ID NO: 13). In some embodiments, the single domain serum albumin binding protein comprises a mutation at amino acid position 6 of CDR1 (SEQ ID NO: 11). In some embodiments, the single domain serum albumin binding protein comprises a mutation at amino acid position 6 of CDR1 (SEQ ID NO: 11) and amino acid position 13 of CDR2 (SEQ ID NO: 12). In some embodiments, the single domain serum albumin binding protein comprises a mutation at amino acid position 6 of CDR1 (SEQ ID NO: 11), amino acid positions 7 and 15 of CDR2 (SEQ ID NO: 12), and amino acid position 6 of CDR3 (SEQ ID NO: 13). In some embodiments, the single domain serum albumin binding protein comprises a mutation at amino acid position 4 of CDR1 (SEQ ID NO: 11) and amino acid position 6 of CDR3 (SEQ ID NO: 13). In some embodiments, the single domain serum albumin binding protein comprises a mutation at amino acid position 6 of CDR1 (SEQ ID NO: 11) and amino acid position 7 of CDR2 (SEQ ID NO: 12).In some embodiments, the single domain serum albumin binding protein comprises a mutation at amino acid position 6 of CDR1 (SEQ ID NO: 11) and amino acid positions 7 and 13 of CDR2 (SEQ ID NO: 12). In some embodiments, the single domain serum albumin binding protein comprises a mutation at amino acid position 6 of CDR1 (SEQ ID NO: 11) and amino acid position 6 of CDR3 (SEQ ID NO: 13). In some embodiments, the single domain serum albumin binding protein comprises a mutation at amino acid position 6 of CDR1 (SEQ ID NO: 11), amino acid position 7 of CDR2 (SEQ ID NO: 12), and amino acid position 6 of CDR3 (SEQ ID NO: 13). In some embodiments, the single domain serum albumin binding protein comprises a mutation at amino acid position 6 of CDR1 (SEQ ID NO: 11), amino acid position 7 and 13 of CDR2 (SEQ ID NO: 12), and amino acid position 6 of CDR3 (SEQ ID NO: 13). In some embodiments, the single domain serum albumin binding protein comprises an amino acid sequence wherein amino acid position 6 of CDR1 (SEQ ID NO: 11) is mutated to arginine, and wherein the hKd and cKd of the single domain serum albumin binding protein are from about 1 nM to about 5 nM. In some embodiments, the single domain serum albumin binding protein comprises an amino acid sequence wherein amino acid position 6 of CDR1 (SEQ ID NO: 11) is mutated to arginine, and amino acid position 13 of CDR2 (SEQ ID NO: 12) is mutated to glutamic acid, and wherein the hKd and cKd of the single domain serum albumin binding protein are from about 1 nM to about 5 nM. In some embodiments, the single domain serum albumin binding protein comprises an amino acid sequence wherein amino acid position 6 of CDR1 (SEQ ID NO: 11) is mutated to lysine, amino acid positions 7 and 15 of CDR2 (SEQ ID NO: 12) are mutated to alanine and leucine, respectively, and amino acid position 6 of CDR3 (SEQ ID NO: 13) is mutated to lysine, and wherein the hKd and cKd of the single domain serum albumin binding protein are from about 1 nM to about 5 nM. In some embodiments, the single domain serum albumin binding protein comprises an amino acid sequence wherein amino acid position 4 of CDR1 (SEQ ID NO: 11) is mutated to tyrosine, and amino acid position 6 of CDR3 (SEQ ID NO: 13) is mutated to lysine, and wherein the hKd and cKd of the single domain serum albumin binding protein are from about 1 nM to about 5 nM.In some embodiments, the single domain serum albumin binding protein comprises an amino acid sequence wherein amino acid position 6 of CDR1 (SEQ ID NO: 11) is mutated to lysine, amino acid position 7 of CDR2 (SEQ ID NO: 12) is mutated to threonine, and wherein the hKd and cKd of the single domain serum albumin binding protein are from about 1 nM to about 5 nM. In some embodiments, the single domain serum albumin binding protein comprises an amino acid sequence wherein amino acid position 6 of CDR1 (SEQ ID NO: 11) is mutated to lysine, amino acid positions 7 and 13 of CDR2 (SEQ ID NO: 12) are mutated to threonine and glutamic acid, respectively, and wherein the hKd and cKd of the single domain serum albumin binding protein are from about 1 nM to about 5 nM. In some embodiments, the single domain serum albumin binding protein comprises an amino acid sequence wherein amino acid position 6 of CDR1 (SEQ ID NO: 11) is mutated to arginine, amino acid position 6 of CDR3 (SEQ ID NO: 12) is mutated to lysine, and wherein the hKd and cKd of the single domain serum albumin binding protein are from about 5 nM to about 10 nM. In some embodiments, the single domain serum albumin binding protein comprises an amino acid sequence wherein amino acid position 6 of CDR1 (SEQ ID NO: 11) is mutated to lysine, amino acid position 7 of CDR2 (SEQ ID NO: 12) is mutated to arginine, amino acid position 6 of CDR3 (SEQ ID NO: 13) is mutated to valine, and wherein the hKd and cKd of the single domain serum albumin binding protein are from about 1 nM to about 5 nM. In some embodiments, the single domain serum albumin binding protein comprises an amino acid sequence wherein amino acid position 6 of CDR1 (SEQ ID NO: 11) is mutated to lysine, amino acid positions 7 and 13 of CDR2 (SEQ ID NO: 12) are mutated to arginine and glutamic acid, respectively, and amino acid position 6 of CDR3 (SEQ ID NO: 13) is mutated to valine, and wherein the single domain serum albumin binding protein has a hKd and cKd of about 1 nM to about 5 nM.

[0015] In another embodiment, provided herein is a polynucleotide encoding a single domain serum albumin binding protein according to the present disclosure. Further embodiments describe vectors comprising a polynucleotide as disclosed herein. Another embodiment describes a host cell transformed with a vector according to the present disclosure. In one embodiment, a pharmaceutical composition is provided, comprising (i) a single domain serum albumin binding protein according to the present disclosure, a polynucleotide according to the present disclosure, a vector according to the present disclosure, or a host cell according to the present disclosure, and (ii) a pharmaceutically acceptable carrier.

[0016] In another embodiment, described herein is a method for producing a single domain serum albumin binding protein according to the present disclosure, the method comprising culturing a host transformed or transfected with a vector comprising a nucleic acid sequence encoding a single domain serum albumin binding protein as described herein under conditions allowing expression of the single domain serum albumin binding protein, and recovering and purifying the produced protein from the culture.

[0017] Further described are methods for treating or ameliorating proliferative diseases, neoplastic diseases, inflammatory diseases, immune disorders, autoimmune diseases, infectious diseases, viral diseases, allergies, parasitic reactions, graft-versus-host disease, or host-versus-graft disease, comprising administering a single domain serum albumin binding protein according to the present disclosure to a subject in need thereof. In some embodiments, the subject is a human. In some embodiments, the method further comprises administering a pharmaceutical agent in combination with a single domain serum albumin binding protein according to the present disclosure.

[0018] In another embodiment, a multispecific binding protein comprising a single domain serum albumin binding protein according to the present disclosure is described. In another embodiment, an antibody comprising a single domain serum albumin binding protein according to the present disclosure is described.

[0019] Further embodiments describe a multispecific antibody, bispecific antibody, sdAb, heavy chain variable domain, peptide or ligand comprising a single domain serum albumin binding protein according to the disclosure. In one embodiment, an antibody comprising a single domain serum albumin binding protein according to the disclosure is provided, wherein the antibody is a single domain antibody. In some embodiments, the single domain antibody is derived from the heavy chain variable region of IgG.

[0020] One embodiment describes a multispecific binding protein or antibody comprising a single domain serum albumin binding protein according to the disclosure and a CD3 binding domain. In one embodiment, a method for treating or ameliorating a proliferative disease, a neoplastic disease, an inflammatory disease, an immune disorder, an autoimmune disease, an infectious disease, a viral disease, an allergy, a parasitic response, a graft versus host disease, or a host versus graft disease is described, comprising administering a multispecific antibody according to the disclosure to a subject in need thereof. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] The novel features of the present invention are particularly set forth in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by referring to the following detailed description and the accompanying drawings which set forth illustrative embodiments utilizing the principles of the present invention, in which:

[0022] Figure 1 Graph depicts specific binding of parental anti-HSA phage to HSA antigen and CD3 antigen as determined by ELISA titration.

[0023] Figure 2 Graph showing cross-reactivity of anti-HSA phage with human, cynomolgus monkey and mouse serum albumin as determined by ELISA titration.

[0024] Figure 3 Binding affinity profiles of nine clones selected for more accurate Kd determination using purified sdAbs are presented.

[0025] Figure 4 The hydrophobic exposure temperatures (T h ℃).

[0026] Figure 5 The propensity of several anti-HSA sdAb variants to form dimers versus monomers at low pH is shown graphically. DETAILED DESCRIPTION

[0027] Although preferred embodiments of the present invention have been shown and described herein, it will be apparent to those skilled in the art that these embodiments are provided by way of example only. Without departing from the present invention, those skilled in the art will now appreciate that many variations, changes and substitutions are possible. It should be understood that various alternatives to the embodiments of the present invention described herein can be used to implement the present invention. The following claims are intended to define the scope of the present invention, and thus encompass methods and structures and their equivalents within the scope of these claims.

[0028] Some definitions

[0029] The terms used herein are for the purpose of describing particular instances only and are not intended to be limiting. As used herein, the singular forms "a", "an", and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise. In addition, to the extent that the terms "includes", "comprising", "having", or variations thereof are used in the detailed description and / or claims, these terms are intended to be inclusive in a manner similar to the term "comprising".

[0030] The term "about" or "approximately" means within an acceptable error range for a particular value determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, e.g., limitations of the measurement system. For example, depending on the practice of a given value, "about" can mean within 1 or more than 1 standard deviation. Where specific values ​​are described in the application and claims, the term "about" should be considered to mean an acceptable error range for that specific value unless otherwise indicated.

[0031] The terms "individual," "patient," or "subject" are used interchangeably. None of these terms require or are limited to situations characterized by supervision (e.g., continuous or intermittent) by a health care worker (e.g., a physician, registered nurse, nurse practitioner, physician assistant, nursing assistant, or hospice worker).

[0032] The term "framework" or "FR" residues (or regions) refers to variable domain residues other than CDR or hypervariable region residues as defined herein. A "human consensus framework" is a framework representing the most commonly occurring amino acid residues in selected human immunoglobulin VL or VH framework sequences.

[0033] As used herein, "variable region" or "variable domain" refers to the following situation: some parts of the variable domain are widely different in sequence between antibodies and are used in the binding and specificity of each specific antibody to its specific antigen. However, the variability is not evenly distributed throughout the variable domain of the antibody. It is concentrated in three segments called complementary determining regions (CDRs) or hypervariable regions in the light chain and heavy chain variable domains. The more highly conserved parts of the variable domain are called frameworks (FRs). The variable domains of natural heavy and light chains each contain four FR regions, which mainly adopt a β-folded configuration and are connected by three CDRs, which form a loop connecting the β-folded structure and in some cases form a part of the β-folded structure. The CDRs in each chain are kept together in close proximity by the FR region and, together with the CDRs from the other chain, help form the antigen binding site of the antibody (see Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition, National Institute of Health, Bethesda, Md. (1991)). Although the constant domain does not directly participate in the binding of the antibody to the antigen, it exhibits various effector functions, such as the antibody's participation in antibody-dependent cellular toxicity. "According to the variable domain residue numbering of Kabat" or "according to the amino acid position numbering of Kabat" and its variations refer to the numbering system of the heavy chain variable domain or light chain variable domain compiled by Kabat et al., Sequences of Proteins of Immunological Interest, the fifth edition of Public Health Service, National Institutes of Health, Bethesda, Md. (1991). Using this numbering system, the actual linear amino acid sequence may contain reduced or added amino acids, which correspond to the shortening or insertion of the FR or CDR of the variable domain. For example, the heavy chain variable domain may include a single amino acid insertion after residue 52 of H2 (residue 52a according to Kabat) and an insertion residue after heavy chain FR residue 82 (e.g., residues 82a, 82b and 82c, etc. according to Kabat). The Kabat numbering of the residues of a given antibody can be determined by comparing the antibody sequence in the homology region with the sequence of the "standard" Kabat numbering. This does not mean that the CDRs of the present disclosure necessarily correspond to the Kabat numbering convention.

[0034] As used herein, "percentage (%) of amino acid sequence identity" relative to a sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical to the amino acid residues in a particular sequence after the sequences are aligned and gaps are introduced (if necessary) to achieve the maximum percentage of sequence identity, and any conservative substitutions are not considered to be part of the sequence identity. Alignment for the purpose of determining percentage of amino acid sequence identity can be achieved in various ways within the skill of the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithm required for achieving maximum alignment over the full length of the compared sequence.

[0035] As used herein, "elimination half-life" is used in its ordinary sense, as described in Goodman and Gillman's The Pharmaceutical Basis of Therapeutics 21-25 (Alfred Goodman Gilman, Louis S. Goodman and Alfred Gilman, eds., 6th edition 1980). In short, the term is intended to include a quantitative measure of the time course of drug elimination. The elimination of most drugs is exponential (i.e., follows first-order kinetics) because the drug concentration is usually not close to the concentration required for saturation of the elimination process. The rate of an exponential process can be determined by its rate constant, k, or by its half-life, t. 1 / 2 The rate constant k represents the fractional change per unit time, and the half-life t 1 / 2 It represents the time required for the process to complete 50%. The units of these two constants are time -1 and time. The first-order rate constant and half-life of a reaction are simply related (k×t 1 / 2 =0.693) and can be interchanged accordingly. Since first-order elimination kinetics indicate that a constant fraction of drug is lost per unit time, a plot of the logarithm of drug concentration versus time is linear after the initial distribution phase (i.e., after drug absorption and distribution are complete). The half-life of drug elimination can be accurately determined from such a plot.

[0036] As used herein, the term "binding affinity" refers to the affinity of a protein described in the present disclosure for its binding target, and is expressed numerically using a "Kd" value. If two or more proteins are shown to have comparable binding affinities for their binding targets, then the Kd values ​​for binding of each protein to its binding target are within ±2 times of each other. If two or more proteins are shown to have comparable binding affinities for a single binding target, then the Kd values ​​for binding of each protein to the single binding target are within ±2 times of each other. If a protein is shown to bind two or more targets with comparable binding affinities, then the Kd values ​​for binding of the protein to the two or more targets are within ±2 times of each other. Generally, higher Kd values ​​correspond to weaker binding. In some embodiments, using BIAcore TM -2000 or BIAcore TM "Kd" is measured by radiolabeled antigen binding assay (RIA) or surface plasmon resonance assay using a BIAcore-3000 (BIAcore, Inc., Piscataway, NJ). In certain embodiments, BIAcore TM -2000 or BIAcore TM The "association rate" or "association rate" or "association rate" or "kon" and the "dissociation rate" or "dissociation rate" or "dissociation rate" or "koff" are measured by surface plasmon resonance technology using a BIAcore-3000 (BIAcore, Inc., Piscataway, NJ). In other embodiments, the Systems (Pall Life Sciences) were used to determine “Kd”, “kon” and “koff”.

[0037] Single domain serum albumin binding proteins, pharmaceutical compositions, and nucleic acids, recombinant expression vectors, and host cells for preparing such single domain serum albumin binding proteins are described herein. Methods of preventing and / or treating diseases, conditions, and disorders using the disclosed single domain serum albumin binding proteins are also provided. The single domain serum albumin binding proteins are capable of specifically binding to serum albumin. In some embodiments, the single domain serum albumin binding proteins comprise other domains, such as a CD3 binding domain and binding domains for other target antigens.

[0038] Single domain serum albumin binding protein

[0039] Single-domain serum albumin binding proteins are contemplated herein. Serum albumin is produced by the liver, exists in a form dissolved in plasma, and is the most abundant blood protein in mammals. Albumin is essential for maintaining the turgor pressure required for the proper distribution of body fluids between blood vessels and body tissues; in the absence of albumin, high pressure in blood vessels forces more fluid out and into tissues. It also acts as a plasma carrier by nonspecific binding to several hydrophobic steroid hormones, and as a transporter for hemin and fatty acids. Human serum albumin (HSA) (molecular weight ~ 67kDa) is the most abundant protein in plasma, present at about 50mg / ml (600μM), and has a half-life of about 20 days in humans. HSA is used to maintain plasma pH, contributes to colloid blood pressure, acts as a carrier for many metabolites and fatty acids, and acts as a major drug transporter in plasma. In some embodiments, the single-domain serum albumin binding protein binds to HSA. In some embodiments, the single-domain serum albumin binding protein binds to serum albumin from cynomolgus monkeys. In some embodiments, the single domain serum albumin binding protein binds to HSA and serum albumin from cynomolgus monkey. In some embodiments, the single domain serum albumin binding protein also binds to mouse serum albumin. In some embodiments, the binding affinity to mouse serum albumin is about 1.5 to about 20 times weaker than the binding affinity to human or cynomolgus monkey serum albumin.

[0040] Non-covalent association with albumin prolongs the elimination half-life of short-lived proteins. For example, intravenous administration of recombinant fusions of albumin binding domains to Fab fragments to mice and rabbits resulted in a 25-fold and 58-fold decrease in in vivo clearance and a 26-fold and 37-fold increase in half-life, respectively, compared to administration of the Fab fragment alone. In another example, where insulin was acylated with fatty acids to promote association with albumin, a persistent effect was observed when injected subcutaneously in rabbits or pigs. In summary, these studies demonstrate a link between albumin binding and prolonged action / serum half-life.

[0041] In some embodiments, the single-domain serum albumin binding protein described herein is a single-domain antibody, such as a heavy chain variable domain (VH) specific for serum albumin, a variable domain (VHH) of a sdAb from a camelid family, a peptide, a ligand, or a small molecule entity. In some embodiments, the single-domain serum albumin binding protein described herein is a single-domain antibody, such as a heavy chain variable domain (VH) specific for HSA, a variable domain (VHH) of a sdAb from a camelid family, a peptide, a ligand, or a small molecule entity. In some embodiments, the serum albumin binding domain of the single-domain serum albumin binding protein described herein is any domain that binds to serum albumin, including but not limited to domains from monoclonal antibodies, polyclonal antibodies, recombinant antibodies, human antibodies, and humanized antibodies. In certain embodiments, the serum albumin binding domain is a single-domain antibody. In other embodiments, the serum albumin binding domain is a peptide. In further embodiments, the serum albumin binding domain is a small molecule. It is contemplated that the single domain serum albumin binding protein is quite small, and in some embodiments is no greater than 25 kD, no greater than 20 kD, no greater than 15 kD, or no greater than 10 kD. In some cases, if the single domain serum albumin binding protein is a peptide or small molecule entity, it is 5 kD or less.

[0042] In some embodiments, the single domain serum albumin binding protein described herein is a half-life extension domain, which provides altered pharmacodynamics and pharmacokinetics to the single domain serum albumin binding protein itself. As described above, the half-life extension domain extends the elimination half-life. The half-life extension domain also changes pharmacodynamic properties, including changing the tissue distribution, penetration and diffusion of the single domain serum albumin binding protein. In some embodiments, compared with proteins without half-life extension domains, the half-life extension domain provides improved tissue (including tumor) targeting, tissue distribution, tissue penetration, diffusion within the tissue and enhanced efficacy. In one embodiment, the treatment method effectively and efficiently utilizes a smaller amount of single domain serum albumin binding protein, resulting in reduced side effects, such as reduced cytotoxicity of non-tumor cells.

[0043] In addition, the binding affinity of a single domain serum albumin binding protein to its binding target can be selected so as to target a specific elimination half-life in a particular single domain serum albumin binding protein. Thus, in some embodiments, the single domain serum albumin binding protein has a high binding affinity to its binding target. In other embodiments, the single domain serum albumin binding protein has a medium binding affinity to its binding target. In other embodiments, the single domain serum albumin binding protein has a low or minute binding affinity to its binding target. Exemplary binding affinities include K values ​​of 10 nM or less (high), 10 nM to 100 nM (medium), and greater than 100 nM (low). D As described above, the binding affinity of the single domain serum albumin binding protein to the binding target is determined by known methods such as surface plasmon resonance (SPR).

[0044] In certain embodiments, the single domain serum albumin binding proteins disclosed herein bind to HSA with a human Kd (hKd). In certain embodiments, the single domain serum albumin binding proteins disclosed herein bind to cynomolgus monkey serum albumin with a cynomolgus monkey Kd (cKd). In certain embodiments, the single domain serum albumin binding proteins disclosed herein bind to cynomolgus monkey serum albumin with a cynomolgus monkey Kd (cKd) and bind to HSA with a human Kd (hKd). In some embodiments, the hKd ranges from 1 nM to 100 nM. In some embodiments, the hKd ranges from 1 nM to 10 nM. In some embodiments, the cKd ranges from 1 nM to 100 nM. In some embodiments, the cKd ranges from 1 nM to 10 nM. In some embodiments, the hKd and cKd range from about 1 nM to about 5 nM or about 5 nM to 10 nM. In some embodiments, the single domain serum albumin binding protein binds to a serum albumin selected from human serum albumin, cynomolgus serum albumin, and mouse serum albumin. In some embodiments, the single domain serum albumin binding protein binds to human serum albumin, cynomolgus serum albumin, and mouse serum albumin with comparable binding affinity (Kd). In some embodiments, the single domain serum albumin binding protein binds to human serum albumin with a human Kd (hKd) of about 1 nM to about 10 nM, and binds to cynomolgus serum albumin with a cynomolgus Kd (cKd) of 1 nM to 10 nM. In some embodiments, the single domain serum albumin binding protein binds to mouse serum albumin with a mouse Kd (mKd) of about 10 nM to about 50 nM.

[0045] In some embodiments, the hKd is about 1.5 nM, about 1.6 nM, about 1.7 nM, about 1.8 nM, about 1.9 nM, about 2 nM, about 2.1 nM, about 2.2 nM, about 2.3 nM, about 2.4 nM, about 2.5 nM, about 2.6 nM, about 2.7 nM, about 2.8 nM, about 2.9 nM, about 3 nM, 3.1 nM, about 3.2 nM, about 3.4 nM, about 3.5 nM, about 3.6 nM, about 3.7 nM, about 3.8 nM, about 3.9 nM, about 4 nM, 4.1 nM, about 4.2 nM, about 4.3 nM, about 4.4 nM, about 4.5 nM, about 4.6 nM, about 4.7 nM, about 4.8 nM, about 4.9 nM, about 5. About 3.2nM, about 3.3nM, about 3.4nM, about 3.5nM, about 3.6nM, about 3.7nM, about 3.8nM, about 3.9nM, about 4nM, about 4.5nM, about 5nM, about 6, about 6.5nM, about 7nM, about 7.5nM, about 8nM, about 8.5nM, about 9.0nM, about 9.5nM or about 10nM.

[0046] In some embodiments, the cKd is about 1.5 nM, about 1.6 nM, about 1.7 nM, about 1.8 nM, about 1.9 nM, about 2 nM, about 2.1 nM, about 2.2 nM, about 2.3 nM, about 2.4 nM, about 2.5 nM, about 2.6 nM, about 2.7 nM, about 2.8 nM, about 2.9 nM, about 3 nM, 3.1 nM, about 3.2 nM, about 3.4 nM, about 3.6 nM, about 3.7 nM, about 3.8 nM, about 3.9 nM, about 4 nM, 4.1 nM, about 4.2 nM, about 4.3 nM, about 4.4 nM, about 4.5 nM, about 4.6 nM, about 4.7 nM, about 4.8 nM, about 4.9 nM, about 4.1 nM, about 4. About 3.2nM, about 3.3nM, about 3.4nM, about 3.5nM, about 3.6nM, about 3.7nM, about 3.8nM, about 3.9nM, about 4nM, about 4.5nM, about 5nM, about 6, about 6.5nM, about 7nM, about 7.5nM, about 8nM, about 8.5nM, about 9.0nM, about 9.5nM or about 10nM.

[0047] In some embodiments, the mKd is about 10 nM, about 11 nM, about 12 nM, about 13 nM, about 14 nM, about 15 nM, about 16 nM, about 17 nM, about 18 nM, about 19 nM, about 20 nM, about 21 nM, about 22 nM, about 23 nM, about 24 nM, about 25 nM, about 26 nM, about 27 nM, about 28 nM, about 29 nM, about 30 nM, about 31 nM, about 32 nM, about 33 nM, about 34 nM, about 35 nM, about 36 nM, about 37, about 38 nM, about 39 nM, about 40 nM, about 41 nM, about 42 nM, about 43 nM, about 44 nM, about 45 nM, about 46 nM, about 47 nM, about 48 nM, or about 50 nM.

[0048] In some embodiments, the single domain serum albumin binding protein has an amino acid sequence selected from SEQ ID NO.4, SEQ ID NO.5, SEQ ID NO.6, SEQ ID NO.7, SEQ ID NO.8, SEQ ID NO.9, SEQ IN NO.25, SEQ ID NO.26 and SEQ ID NO.27.

[0049] In some embodiments, the single domain serum albumin binding protein has an amino acid sequence as shown in SEQ ID NO.4, and hKd and cKd are about 1 nM to about 5 nM. In some embodiments, the single domain serum albumin binding protein has an amino acid sequence as shown in SEQ ID NO.4, and hKd is about 2.3 nM and cKd is about 2.4 nM. In some embodiments, the single domain serum albumin binding protein has an amino acid sequence as shown in SEQ ID NO.25, and hKd and cKd are about 1 nM to about 5 nM. In some embodiments, the single domain serum albumin binding protein has an amino acid sequence as shown in SEQ ID NO.25, and hKd is about 2.1 nM and cKd is about 2.2 nM. In some embodiments, the single domain serum albumin binding protein has an amino acid sequence as shown in SEQ ID NO.5, and hKd and cKd are about 1 nM to about 5 nM. In some embodiments, the single domain serum albumin binding protein has an amino acid sequence as shown in SEQ ID NO.5, and the hKd is about 1.9 nM and the cKd is about 1.7 nM. In some embodiments, the single domain serum albumin binding protein has an amino acid sequence as shown in SEQ ID NO.6, and the hKd and cKd are about 1 nM to about 5 nM. In some embodiments, the single domain serum albumin binding protein has an amino acid sequence as shown in SEQ ID NO.6, and the hKd is about 3.2 nM and the cKd is about 3.6 nM. In some embodiments, the single domain serum albumin binding protein has an amino acid sequence as shown in SEQ ID NO.7, and the hKd and cKd are about 1 nM to about 5 nM. In some embodiments, the single domain serum albumin binding protein has an amino acid sequence as shown in SEQ ID NO.7, and the hKd is about 2.7 nM and the cKd is about 2.6 nM. In some embodiments, the single domain serum albumin binding protein has an amino acid sequence as shown in SEQ ID NO.26, and hKd and cKd are about 1 nM to about 5 nM. In some embodiments, the single domain serum albumin binding protein has an amino acid sequence as shown in SEQ ID NO.26, and hKd is about 2.1 nM and cKd is about 2 nM. In some embodiments, the single domain serum albumin binding protein has an amino acid sequence as shown in SEQ ID NO.8, and hKd and cKd are about 5 nM to about 10 nM. In some embodiments, the single domain serum albumin binding protein has an amino acid sequence as shown in SEQ ID NO.8, and hKd is about 6 nM and cKd is about 7.5 nM.In some embodiments, the single domain serum albumin binding protein has an amino acid sequence as shown in SEQ ID NO.9, and wherein hKd and cKd are about 1 nM to about 5 nM. In some embodiments, the single domain serum albumin binding protein has an amino acid sequence as shown in SEQ ID NO.9, and wherein hKd is about 2.2 nM and cKd is about 2.3 nM. In some embodiments, the single domain serum albumin binding protein has an amino acid sequence as shown in SEQ ID NO.27, and wherein hKd and cKd are about 1 nM to about 5 nM. In some embodiments, the single domain serum albumin binding protein has an amino acid sequence as shown in SEQ ID NO.27, and wherein hKd is about 1.6 nM and cKd is about 1.6 nM.

[0050] In some embodiments, the single domain serum albumin binding protein has an amino acid sequence as shown in SEQ ID NO.4, and has an mKd of about 17nM. In some embodiments, the single domain serum albumin binding protein has an amino acid sequence as shown in SEQ ID NO.5, and has an mKd of about 12nM. In some embodiments, the single domain serum albumin binding protein has an amino acid sequence as shown in SEQ ID NO.6, and has an mKd of about 33nM. In some embodiments, the single domain serum albumin binding protein has an amino acid sequence as shown in SEQ ID NO.7, and has an mKd of about 14nM. In some embodiments, the single domain serum albumin binding protein has an amino acid sequence as shown in SEQ ID NO.9, and has an mKd of about 16nM. In some embodiments, the single domain serum albumin binding protein has an amino acid sequence as shown in SEQ ID NO.25, and has an mKd of about 17nM. In some embodiments, the single domain serum albumin binding protein has an amino acid sequence as shown in SEQ ID NO. 26, and has an mKd of about 17 nM. In some embodiments, the single domain serum albumin binding protein has an amino acid sequence as shown in SEQ ID NO. 27, and has an mKd of about 16 nM.

[0051] In some embodiments, the ratio of hKd to cKd (hKd:cKd) is in the range of about 20:1 to about 1:2.

[0052] In some embodiments, the single domain serum albumin binding protein has an elimination half-life of at least 1 hour, at least 2 hours, at least 4 hours, at least 6 hours, at least 12 hours, at least 20 hours, at least 25 hours, at least 30 hours, at least 35 hours, at least 40 hours, at least 45 hours, at least 50 hours, or at least 100 hours.

[0053] CD3 binding domain

[0054] The specificity of T cell responses is mediated by the recognition of antigens (displayed in the context of the major histocompatibility complex MHC) by the T cell receptor complex. As part of the T cell receptor complex, CD3 is a protein complex that contains the CD3γ (gamma) chain, the CD3δ (delta) chain, and two CD3ε (epsilon) chains present on the cell surface. CD3 associates with the α (alpha) and β (beta) chains of the T cell receptor (TCR) and together with CD3ζ (zeta) constitutes the T cell receptor complex. Clustering of CD3 on T cells (such as by immobilized anti-CD3 antibodies) leads to T cell activation, which is similar to the engagement of the T cell receptor, but does not rely on its clone-specific specificity.

[0055] In one aspect, described herein are multispecific proteins comprising a single domain serum albumin binding protein according to the present disclosure. In some embodiments, the multispecific protein further comprises a domain that specifically binds to CD3. In some embodiments, the multispecific protein further comprises a domain that specifically binds to human CD3. In some embodiments, the multispecific protein further comprises a domain that specifically binds to CD3γ. In some embodiments, the multispecific protein further comprises a domain that specifically binds to CD3δ. In some embodiments, the multispecific protein further comprises a domain that specifically binds to CD3ε.

[0056] In additional embodiments, the multispecific protein further comprises a domain that specifically binds to a T cell receptor (TCR). In some embodiments, the multispecific protein further comprises a domain that specifically binds to the α chain of the TCR. In some embodiments, the multispecific protein further comprises a domain that specifically binds to the β chain of the TCR.

[0057] In certain embodiments, the CD3 binding domain of a multispecific protein comprising a single-domain serum albumin binding protein described herein not only exhibits strong CD3 binding affinity to human CD3, but also shows excellent cross-reactivity with the corresponding cynomolgus CD3 protein. In some cases, the CD3 binding domain of the multispecific protein is cross-reactive with CD3 from cynomolgus monkey. In some cases, with respect to CD3 binding to human: cynomolgus monkey CD3 D The ratio of (hKd:cKd) is 20:1 to 1:2.

[0058] In some embodiments, the CD3 binding domain of the multispecific protein comprising a single domain serum albumin binding protein described herein can be any domain that binds to CD3, including but not limited to domains from monoclonal antibodies, polyclonal antibodies, recombinant antibodies, human antibodies, humanized antibodies, or antigen-binding fragments of CD3 binding antibodies, such as single domain antibodies (sdAb), Fab, Fab', F(ab)2 and Fv fragments, fragments consisting of one or more CDRs, single chain antibodies (e.g., single chain Fv fragments (scFv)), disulfide-stabilized (dsFv) Fv fragments, heteroconjugate antibodies (e.g., bispecific antibodies), pFv fragments, heavy chain monomers or dimers, light chain monomers or dimers, and dimers consisting of one heavy chain and one light chain. In some cases, it is beneficial that the CD3 binding domain is derived from the same species in which the multispecific protein comprising a single domain serum albumin binding protein described herein will ultimately be used. For example, for use in humans, it may be beneficial for the CD3 binding domain of a multispecific protein comprising a single domain serum albumin binding protein described herein to comprise human or humanized residues from the antigen binding domain of an antibody or antibody fragment.

[0059] Thus, in one aspect, the antigen binding domain comprises a humanized or human antibody or antibody fragment or a murine antibody or antibody fragment. In one embodiment, the humanized or human anti-CD3 binding domain comprises one or more (e.g., all three) of the light chain complementary determining region 1 (LC CDR1), light chain complementary determining region 2 (LC CDR2), and light chain complementary determining region 3 (LC CDR3) of the humanized or human anti-CD3 binding domain described herein, and / or one or more (e.g., all three) of the heavy chain complementary determining region 1 (HC CDR1), heavy chain complementary determining region 2 (HC CDR2), and heavy chain complementary determining region 3 (HC CDR3) of the humanized or human anti-CD3 binding domain described herein, e.g., the humanized or human anti-CD3 binding domain comprises one or more, e.g., all three LC CDRs, and one or more, e.g., all three HC CDRs.

[0060] In some embodiments, the humanized or human anti-CD3 binding domain comprises a humanized or human light chain variable region that is specific for CD3, wherein the light chain variable region that is specific for CD3 comprises a human or non-human light chain CDR in a human light chain framework region. In some cases, the light chain framework region is a lambda light chain framework. In other cases, the light chain framework region is a kappa light chain framework.

[0061] In some embodiments, the humanized or human anti-CD3 binding domain comprises a humanized or human heavy chain variable region that is specific for CD3, wherein the heavy chain variable region that is specific for CD3 comprises human or non-human heavy chain CDRs in a human heavy chain framework region.

[0062] In some cases, the complementarity determining regions of the heavy and / or light chains are derived from known anti-CD3 antibodies, e.g., muromonab-CD3 (OKT3), otelizumab (TRX4), telizumab (MGA031), visilizumab (Nuvion), SP34, TR-66 or X35-3, VIT3, BMA030 (BW264 / 56), CLB-T3 / 3, CRIS7, YTH12.5, F111-409, CLB-T3.4.2, TR-66, WT32, SPv-T3b, 11D8, XIII-141, XIII-46, XIII-87, 12F6, T3 / RW2-8C8, T3 / RW2-4B6, OKT3D, M-T301, SMC2, F101.01, UCHT-1, and WT-31.

[0063] The affinity for binding to CD3 can be determined by, for example, the ability of a multispecific protein comprising a single domain serum albumin binding protein itself or its CD3 binding domain to bind to CD3 coated on an assay plate, CD3 displayed on the surface of a microbial cell, CD3 in a solution, etc. The binding activity of a multispecific protein comprising a single domain serum albumin binding protein itself or its CD3 domain to CD3 according to the present disclosure can be determined as follows: a ligand (e.g., CD3) or the multispecific protein itself or its CD3 binding domain is immobilized to beads, a substrate, a cell, etc. The reagent can be added to a suitable buffer and the binding partner can be incubated at a given temperature for a period of time. After washing to remove unbound material, the bound protein can be released using, for example, SDS, a high pH buffer, etc., and analyzed by, for example, surface plasmon resonance (SPR).

[0064] Target antigen binding domain

[0065] In certain embodiments, the multispecific binding proteins comprising a single domain serum albumin binding protein described herein further comprise, in addition to the serum albumin binding domain and the CD3 domain, a domain that binds to a target antigen. The target antigen is involved in and / or is associated with a disease, disorder or condition. In particular, the target antigen is associated with a proliferative disease, a neoplastic disease, an inflammatory disease, an immune disorder, an autoimmune disease, an infectious disease, a viral disease, an allergic reaction, a parasitic reaction, a graft versus host disease, or a host versus graft disease. In some embodiments, the target antigen is a tumor antigen expressed on a tumor cell. Alternatively, in some embodiments, the target antigen is associated with a pathogen such as a virus or a bacterium.

[0066] In some embodiments, the target antigen is a cell surface molecule, such as a protein, lipid, or polysaccharide. In some embodiments, the target antigen is on a tumor cell, a virus-infected cell, a bacterially infected cell, a damaged red blood cell, an arterial plaque cell, or a fibrotic tissue cell.

[0067] The design of multispecific binding proteins comprising single domain serum albumin binding proteins according to the present disclosure allows the binding domain of the target antigen to be flexible, because the binding domain of the target antigen can be any type of binding domain, including but not limited to domains from monoclonal antibodies, polyclonal antibodies, recombinant antibodies, human antibodies, and humanized antibodies. In some embodiments, the binding domain of the target antigen is a single chain variable fragment (scFv), a single domain antibody such as a heavy chain variable domain (VH), a light chain variable domain (VL), and a variable domain (VHH) of sdAb from camelid sources. In other embodiments, the binding domain of the target antigen is a non-Ig binding domain, i.e., an antibody mimetic, such as anticalin, affilin, affibody molecule, affimer, affitin, alphabody, avimer, DARPin, fynomer, kunitz domain peptide, and a single antibody (monobody). In further embodiments, the binding domain of the target antigen is a ligand or peptide that binds or associates with the target antigen. In further embodiments, the binding domain of the target antigen is a knottin. In a further embodiment, the binding domain for the target antigen is a small molecule entity.

[0068] Modification of single domain serum albumin binding proteins

[0069] The single domain serum albumin binding proteins described herein include derivatives or analogs in which (i) amino acids are replaced with amino acid residues not encoded by the genetic code, (ii) the mature polypeptide is fused to another compound such as polyethylene glycol, or (iii) additional amino acids are fused to the protein, such as a leader sequence or a secretory sequence or a sequence that blocks an immunogenic domain and / or a sequence for purification of the protein.

[0070] Typical modifications include, but are not limited to, acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, covalent cross-link formation, cystine formation, pyroglutamate formation, formylation, gamma carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer RNA-mediated addition of amino acids to proteins, such as arginylation, and ubiquitination.

[0071] Modifications are made at any position in the single domain serum albumin binding proteins described herein, including the peptide backbone, the amino acid side chains, and the amino or carboxyl termini. Certain common peptide modifications that can be used to modify single domain serum albumin binding proteins include glycosylation, lipid attachment, sulfation, γ-carboxylation of glutamic acid residues, hydroxylation, blocking of the amino or carboxyl groups or both in the polypeptide by covalent modification, and ADP-ribosylation.

[0072] Polynucleotide encoding a single domain serum albumin binding protein

[0073] In some embodiments, polynucleotide molecules encoding the single domain serum albumin binding proteins described herein are also provided. In some embodiments, the polynucleotide molecules are provided in the form of DNA constructs. In other embodiments, the polynucleotide molecules are provided in the form of messenger RNA transcripts.

[0074] The polynucleotide molecule is constructed by known methods, for example by combining genes encoding three binding domains separated by a peptide linker, or in other embodiments directly linked by peptide bonds, into a single gene construct, which is operably linked to a suitable promoter and, optionally, a suitable transcription terminator, and expressed in bacteria or other suitable expression systems, such as CHO cells.

[0075] In some embodiments, polynucleotide molecules encoding multispecific binding proteins comprising a single domain serum albumin binding protein according to the present disclosure are also provided. In some embodiments, the polynucleotide encoding the multispecific binding protein further comprises a coding sequence for a CD3 binding domain. In some embodiments, the polynucleotide encoding the multispecific binding protein further comprises a coding sequence for a target antigen binding domain. In some embodiments, the polynucleotide encoding the multispecific binding protein further comprises a coding sequence for a CD3 binding domain and a target antigen binding domain. In some embodiments, the polynucleotide molecule is provided in the form of a DNA construct. In other embodiments, the polynucleotide molecule is provided in the form of a messenger RNA transcript. In embodiments where the target antigen binding domain is a small molecule, the polynucleotide contains genes encoding a serum albumin binding domain and a CD3 binding domain. In embodiments where the half-life extension domain is a small molecule, the polynucleotide contains genes encoding a domain that binds to CD3 and a target antigen. Depending on the vector system and host employed, any number of suitable transcription and translation elements may be used, including constitutive and inducible promoters. The promoter is selected so that it drives expression of the polynucleotide in the corresponding host cell.

[0076] In some embodiments, the polynucleotide is inserted into a vector, preferably an expression vector, which represents a further embodiment. The recombinant vector can be constructed according to known methods. Vectors of particular interest include plasmids, phagemids, phage derivatives, viruses (virii) (e.g., retroviruses, adenoviruses, adeno-associated viruses, herpes viruses, lentiviruses, etc.) and cosmids.

[0077] A variety of expression vector / host systems can be used to contain and express the polynucleotide encoding the polypeptide of the single domain serum albumin binding protein. Examples of expression vectors for expression in E. coli are pSKK (Le Gall et al., J Immunol Methods. (2004) 285(1): 111-27), pcDNA5 (Invitrogen) for expression in mammalian cells, PICHIAPINK TM Yeast expression system (Invitrogen), BACUVANCE TM Baculovirus Expression System (GenScript).

[0078] Thus, in some embodiments, a single domain serum albumin binding protein as described herein is produced by introducing a vector encoding a protein as described above into a host cell and culturing the host cell under conditions whereby the protein domain is expressed, which host cell can be isolated and optionally further purified.

[0079] Generation of single-domain serum albumin binding proteins

[0080] In some embodiments, disclosed herein are methods for producing a single domain serum albumin binding protein. In some embodiments, the method comprises culturing a host transformed or transfected with a vector comprising a nucleic acid sequence encoding the single domain serum albumin binding protein under conditions that allow expression of the single domain serum albumin binding protein, and recovering and purifying the produced protein from the culture.

[0081] In further embodiments, methods are provided for improving one or more properties of a single domain serum albumin binding protein and / or a multispecific binding protein comprising a single domain serum albumin binding protein as described herein compared to a reference binding compound, such as affinity, stability, thermostability, cross-reactivity, etc. In some embodiments, a plurality of single substitution libraries are provided, each library corresponding to a different domain or amino acid segment of a single domain serum albumin binding protein or a reference binding compound, such that each member of a single substitution library encodes only a single amino acid change in its corresponding domain or amino acid segment (this allows all potential substitutions in a large protein or protein binding site to be probed with a small number of small libraries). In some embodiments, a plurality of domains form or cover a contiguous sequence of amino acids of a single domain serum albumin binding protein or a reference binding compound. The nucleotide sequences of different single substitution libraries overlap with the nucleotide sequences of at least one other single substitution library. In some embodiments, a plurality of single substitution libraries are designed such that each member overlaps with each member of each single substitution library encoding an adjacent domain.

[0082] Binding compounds expressed by such single displacement libraries are individually selected to obtain a subset of variants of each library, the subset of variants having properties at least as good as those of the reference binding compound, and the resulting library size is reduced (i.e., the number of nucleic acids encoding the selected set of binding compounds is less than the number of nucleic acids encoding the members of the original single displacement library). Such properties include, but are not limited to, affinity for the target compound, stability under various conditions such as heating, high or low pH, enzymatic degradation, cross-reactivity with other proteins, and the like. The selected compounds from each single displacement library are interchangeably referred to herein as "pre-candidate compounds" or "pre-candidate proteins". The nucleic acid sequences encoding the pre-candidate compounds from the separate single displacement libraries are then shuffled in PCR using PCR-based gene shuffling techniques to produce shuffled libraries.

[0083] An exemplary workflow of the screening process is described herein. A library of pre-candidate compounds is generated from a single displacement library and selected for binding to a target protein, after which the pre-candidate library is reorganized to generate a nucleic acid library encoding a candidate compound, which is then cloned into a suitable expression vector such as a phagemid expression system in sequence. The phage expressing the candidate compound is then subjected to one or more rounds of selection to improve the desired properties, such as binding affinity to the target molecule. The target molecule may be adsorbed or otherwise attached to the surface of a well or other reaction vessel, or the target molecule may be derivatized with a binding moiety such as biotin, which may be captured with a complementary moiety such as streptavidin bound to beads such as magnetic beads after incubation with the candidate binding compound for washing. In an exemplary selection scheme, the candidate binding compound is subjected to an extended washing step so that only candidate compounds with a very low dissociation rate from the target molecule are selected. An exemplary washing time for such an embodiment is at least 8 hours; or in other embodiments at least 24 hours; or in other embodiments at least 48 hours; or in other embodiments at least 72 hours. After selection, isolated clones are expanded and subjected to additional selection cycles or analysis, such as by sequencing and by comparative measurements of binding affinity, such as by ELISA, surface plasmon resonance binding, biomembrane interferometry (e.g., Octet system, ForteBio, Menlo Park, CA), etc. In some embodiments, the process is performed to identify one or more single domain serum albumin binding proteins and / or multispecific binding proteins comprising single domain serum albumin binding proteins that have improved thermal stability, improved cross-reactivity with a selected set of binding targets compared to a reference serum albumin binding protein (e.g., a protein having an amino acid sequence of SEQ ID NO. 10). A single substitution library is prepared by changing codons in the VH region of a reference serum albumin binding protein, including codons in the framework region and CDRs; in another embodiment, the positions where codons are changed include CDRs of the heavy chain of the reference serum albumin binding protein, or a subset of such CDRs, such as only CDR1, only CDR2, only CDR3, or a CDR pair. In another embodiment, the positions where codons are changed occur only in the framework region. In some embodiments, the library comprises only single codon changes relative to a reference serum albumin binding protein, which changes are only in the framework regions of the VH numbered in the range of 10 to 250. In another embodiment, the positions where the codons are changed include the CDR3 of the heavy chain of the reference serum albumin binding protein, or a subset of such CDR3. In another embodiment, the number of positions where the VH coding region codons are changed is in the range of 10 to 250, such that at most 100 positions are in the framework regions.After preparing the single displacement libraries as described above, the following steps are performed: (a) expressing each member of each single displacement library individually as a pre-candidate protein; (b) selecting a member of each single displacement library encoding a pre-candidate protein that binds to a binding partner, which binding partner may be different from or the same as the original binding target [e.g., a desired cross-reactive target]; (c) shuffling the members of the selected library in PCR to produce a combinatorial shuffled library; (d) expressing the members of the shuffled library as candidate serum albumin binding proteins; and (e) subjecting the members of the shuffled library to one or more selections to obtain candidate serum albumin binding proteins that bind to the original binding partner, and possibly (f) further selecting the candidate proteins for binding to the desired cross-reactive target, thereby providing nucleic acid-encoded serum albumin binding proteins that have increased cross-reactivity to one or more substances relative to a reference serum albumin binding protein without losing affinity for the original ligand. In another embodiment, the method can be implemented to obtain a serum albumin binding protein with reduced reactivity to a selected cross-reactive substance or compound or epitope by replacing step (f) with the following steps: excluding candidate binding compounds that bind to unwanted cross-reactive compounds from the subset of candidate serum albumin binding proteins one or more times.

[0084] Recent studies have reported that therapeutic antibodies are at risk of degradation through a number of pathways during preparation, storage, and in vivo use. The most common chemical degradation reactions in proteins include deamidation of asparagine (N) and isomerization of aspartic acid (D) residues. In particular, given that N and D residues are involved in antigen recognition, their chemical alterations can lead to severe potency loss. Asparagine and aspartic acid residues are known to share a degradation pathway that proceeds through the formation of a cyclic succinimide intermediate. The formation of succinimide intermediates and their hydrolysis products (aspartate and isoaspartate) at the aspartate site of antibodies represents a stability issue. When isomerization occurs, the chemical structure of the antibody is altered, which can lead to poor stability, such as manifested by aggregation, shorter shelf life. Therefore, in some embodiments of the present disclosure, a single-domain serum albumin binding protein is provided, wherein one or more aspartic acid residues are mutated, thereby reducing the potential for isomerization of the single-domain serum albumin binding protein. In some embodiments, the aspartic acid residue is in CDR2 of the single domain serum albumin binding protein, and the aspartic acid residue is mutated to glutamic acid. In certain embodiments, the aspartic acid residue at position 62 of the protein defined by SEQ ID NO.10 is mutated to glutamic acid (D62E). In some embodiments, the serum albumin binding affinity of the single domain serum albumin protein containing the D62E mutation is not affected by the mutation. In some embodiments, single domain serum albumin binding proteins with and without the D62E mutation have comparable binding affinity to serum albumin.

[0085] Pharmaceutical composition

[0086] In some embodiments, a pharmaceutical composition is also provided, comprising a single domain serum albumin binding protein as described herein, a vector comprising a polynucleotide encoding a polypeptide of a single domain serum albumin binding protein, or a host cell transformed by the vector, and at least one pharmaceutically acceptable carrier. The term "pharmaceutically acceptable carrier" includes, but is not limited to, any carrier that does not interfere with the effectiveness of the biological activity of the component and is non-toxic to the patient to which it is administered. Examples of suitable pharmaceutical carriers are well known in the art and include phosphate buffered saline solutions, water, emulsions such as oil-in-water emulsions, various types of wetting agents, sterile solutions, and the like. Such carriers can be formulated by conventional methods and can be administered to a subject at a suitable dose. Preferably, the composition is sterile. These compositions may also contain adjuvants such as preservatives, emulsifiers, and dispersants. Various antibacterial and antifungal agents may be included to ensure that the action of microorganisms is prevented.

[0087] In some embodiments of the pharmaceutical composition, the single-domain serum albumin binding protein described herein is encapsulated in a nanoparticle. In some embodiments, the nanoparticle is a fullerene, a liquid crystal, a liposome, a quantum dot, a superparamagnetic nanoparticle, a dendrimer, or a nanorod. In other embodiments of the pharmaceutical composition, the single-domain serum albumin binding protein is attached to a liposome. In some cases, the single-domain serum albumin binding protein is conjugated to the surface of the liposome. In some cases, the single-domain serum albumin binding protein is encapsulated in the shell of the liposome. In some cases, the liposome is a cationic liposome.

[0088] The single domain serum albumin binding proteins described herein are contemplated for use as medicaments. Administration is achieved in different ways, for example, by intravenous, intraperitoneal, subcutaneous, intramuscular, topical or intradermal administration. In some embodiments, the route of administration depends on the type of therapy and the type of compound contained in the pharmaceutical composition. The dosage regimen will be determined by the attending physician based on other clinical factors. The dosage for any one patient depends on many factors, including the patient's size, body surface area, age, sex, the specific compound to be administered, the time and route of administration, the type of therapy, overall health, and other concurrently administered drugs. An "effective dose" refers to an amount of active ingredient that is sufficient to affect the course and severity of the disease, thereby resulting in a reduction or alleviation of such pathology, and can be determined using known methods.

[0089] Treatment

[0090] In some embodiments, methods and uses for stimulating the immune system of an individual in need thereof are also provided herein, comprising administering a single domain serum albumin binding protein as described herein or a multispecific binding protein comprising a single domain serum albumin binding protein. In some cases, administration of a single domain serum albumin binding protein as described herein induces and / or maintains cytotoxicity to cells expressing the target antigen. In some cases, cells expressing the target antigen are cancer cells or tumor cells, virally infected cells, bacterially infected cells, autoreactive T cells or B cells, damaged red blood cells, arterial plaques, or fibrotic tissue.

[0091] Also provided herein are methods and uses for treating a disease, disorder or condition associated with a target antigen, comprising administering to an individual in need thereof a single domain serum albumin binding protein as described herein or a multispecific binding protein comprising a single domain serum albumin binding protein. Diseases, disorders or conditions associated with a target antigen include, but are not limited to, viral infections, bacterial infections, autoimmune diseases, transplant rejection, atherosclerosis or fibrosis. In other embodiments, the disease, disorder or condition associated with a target antigen is a proliferative disease, a neoplastic disease, an inflammatory disease, an immune disorder, an autoimmune disease, an infectious disease, a viral disease, an allergic reaction, a parasitic reaction, a graft-versus-host disease or a host-versus-graft disease. In one embodiment, the disease, disorder or condition associated with a target antigen is cancer. In one case, the cancer is a hematological cancer. In another case, the cancer is a solid tumor cancer.

[0092] In some embodiments, as used herein, "treatment" or "treatment" refers to therapeutic treatment, wherein the purpose is to slow down (mitigate) an undesirable physiological condition, disorder or disease, or to obtain a beneficial or desired clinical result. For the purposes described herein, beneficial or desired clinical results include, but are not limited to, alleviation of symptoms; reduction in the extent of the condition, disorder or disease; stabilization (i.e., no deterioration) of the condition, disorder or disease state; delayed onset or slowed progression of the condition, disorder or disease; improvement of the condition, disorder or disease state; and detectable or undetectable relief (partial or complete), or enhancement or improvement of the condition, disorder or disease. Treatment includes inducing a clinically significant response without excessive side effects. Treatment also includes extending survival compared to the expected survival without treatment. In other embodiments, "treatment" or "treatment" refers to preventive measures, wherein the purpose is, for example, in a person susceptible to the disease (e.g., an individual carrying a genetic marker for a disease such as breast cancer), delaying the onset of an undesirable physiological condition, disorder or disease or reducing its severity.

[0093] In some embodiments of the methods described herein, the single domain serum albumin binding proteins described herein or multispecific binding proteins comprising single domain serum albumin binding proteins are administered in combination with agents for treating a particular disease, disorder or condition. Agents include, but are not limited to, therapies involving antibodies, small molecules (e.g., chemotherapeutic drugs), hormones (steroids, peptides, etc.), radiotherapy (gamma rays, X-rays and / or directed delivery of radioisotopes, microwaves, UV radiation, etc.), gene therapy (e.g., antisense therapy, retroviral therapy, etc.), and other immunotherapies. In some embodiments, the single domain serum albumin binding proteins described herein or multispecific binding proteins comprising single domain serum albumin binding proteins are administered in combination with antidiarrheals, antiemetics, analgesics, opioids, and / or nonsteroidal anti-inflammatory agents. In some embodiments, the single domain serum albumin binding proteins described herein or multispecific binding proteins comprising single domain serum albumin binding proteins are administered before, during, or after surgery.

[0094] The present invention provides embodiments including but not limited to the following:

[0095] 1. A single domain serum albumin binding protein comprising complementarity determining regions CDR1, CDR2 and CDR3, wherein

[0096] (a) the amino acid sequence of CDR1 is shown as GFX1X2X3X4FGMS (SEQ ID NO. 1), X1 is threonine, arginine, lysine, serine or proline, X2 is phenylalanine or tyrosine, X3 is serine, arginine or lysine, and X4 is serine, lysine, arginine or alanine;

[0097] (b) the amino acid sequence of CDR2 is as shown in SISGSGX5X6TLYAX7SX8K (SEQ ID NO. 2), X5 is serine, arginine, threonine or alanine, X6 is aspartic acid, histidine, valine or threonine, X7 is aspartic acid, histidine, arginine or serine, and X8 is valine or leucine; and

[0098] (c) The amino acid sequence of CDR3 is GGSLX9X 10 (SEQ ID NO.3), X9 is serine, arginine, threonine or lysine, and X 10 is arginine, lysine, valine, proline or asparagine, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9 and X 10 Different from each other, they are threonine, phenylalanine, serine, serine, serine, aspartic acid, aspartic acid, valine, serine and arginine.

[0099] 2. The single domain serum albumin binding protein of embodiment 1, wherein the protein comprises the formula:

[0100] f1-r1-f2-r2-f3-r3-f4

[0101] wherein r1 is SEQ ID NO.1; r2 is SEQ ID NO.2; and r3 is SEQ ID NO.3; and wherein f1, f2, f3 and f4 are selected framework residues such that the protein is at least 80% identical to the amino acid sequence shown in SEQ ID NO.10.

[0102] 3. The single-domain serum albumin binding protein of embodiment 2, wherein r1 comprises SEQ ID NO.14, SEQ ID NO.15 or SEQ ID NO.16.

[0103] 4. A single-domain serum albumin binding protein as described in embodiment 2, wherein r2 comprises SEQ ID NO.17, SEQ ID NO.18, SEQ ID NO.19, SEQ ID NO.20, SEQ ID NO.21 or SEQ ID NO.22.

[0104] 5. The single-domain serum albumin binding protein as described in embodiment 2, wherein r3 comprises SEQ ID NO.23 or SEQ ID NO.24.

[0105] 6. A single domain serum albumin binding protein as described in any one of embodiments 2-5, wherein r1 comprises SEQ ID NO.14.

[0106] 7. A single domain serum albumin binding protein as described in any of embodiments 2-5, wherein r1 comprises SEQ ID NO.15, r2 is SEQ ID NO.17, and r3 is SEQ ID NO.23.

[0107] 8. A single domain serum albumin binding protein as described in any one of embodiments 2-5, wherein r1 comprises SEQ ID NO.16 and r3 comprises SEQ ID NO.23.

[0108] 9. The single domain serum albumin binding protein of any one of embodiments 2-5, wherein r1 comprises SEQ ID NO.15 and r2 comprises SEQ ID NO.18.

[0109] 10. The single domain serum albumin binding protein of any one of embodiments 2-5, wherein r1 comprises SEQ ID NO.14 and r3 comprises SEQ ID NO.23.

[0110] 11. A single domain serum albumin binding protein as described in any of embodiments 2-5, wherein r1 comprises SEQ ID NO.15, r2 comprises SEQ ID NO.19, and r3 comprises SEQ ID NO.24.

[0111] 12. The single domain serum albumin binding protein of any one of embodiments 2-5, wherein r1 comprises SEQ ID NO.14 and r2 comprises SEQ ID NO.20.

[0112] 13. A single domain serum albumin binding protein as described in any of embodiments 2-5, wherein r1 comprises SEQ ID NO.15 and r2 comprises SEQ ID NO.21.

[0113] 14. A single domain serum albumin binding protein as described in any of embodiments 2-5, wherein r1 comprises SEQ ID NO.15, r2 comprises SEQ ID NO.22, and r3 comprises SEQ ID NO.24.

[0114] 15. A single-domain serum albumin binding protein as described in embodiment 1, wherein the protein has an amino acid sequence selected from SEQ ID NO.4, SEQ ID NO.5, SEQ ID NO.6, SEQ ID NO.7, SEQ ID NO.8, SEQ ID NO.9, SEQIN NO.25, SEQ ID NO.26 and SEQ ID NO.27.

[0115] 16. A single domain serum albumin binding protein as described in any of embodiments 1-15, wherein the protein binds to a serum albumin selected from human serum albumin, cynomolgus monkey serum albumin and mouse serum albumin.

[0116] 17. A single domain serum albumin binding protein as described in any of embodiments 1-16, wherein the protein binds to human serum albumin and cynomolgus monkey serum albumin with comparable binding affinity (Kd).

[0117] 18. A single-domain serum albumin binding protein as described in any of embodiments 1-17, wherein the binding affinity (Kd) of the protein to mouse serum albumin is about 1.5 to about 20 times weaker than the binding affinity (Kd) of the protein to human and cynomolgus monkey serum albumin.

[0118] 19. A single domain serum albumin binding protein as described in any of embodiments 1-18, wherein the protein binds to human serum albumin with a human Kd (hKd) of about 1 nM to about 100 nM, and binds to cynomolgus monkey serum albumin with a cynomolgus monkey Kd (cKd) of 1 nM to 100 nM.

[0119] 20. The single domain serum albumin binding protein of embodiment 19, wherein the hKd and the cKd are from 1 nM to about 5 nM or from about 5 nM to about 10 nM.

[0120] 21. The single domain serum albumin binding protein of embodiment 20, wherein the hKd and the cKd are about 1 nM to about 2 nM, about 2 nM to about 3 nM, about 3 nM to about 4 nM, about 4 nM to about 5 nM, about 5 nM to about 6 nM, about 6 nM to about 7 nM, about 7 nM to about 8 nM, about 8 nM to about 9 nM, or about 9 nM to about 10 nM.

[0121] 22. The single domain serum albumin binding protein of any one of embodiments 16-21, wherein the ratio of said hKd to said cKd (hKd:cKd) is in the range of about 20:1 to about 1:2.

[0122] 23. A single domain serum albumin binding protein as described in any one of embodiments 1-22, wherein the protein comprises the amino acid sequence shown in SEQ ID NO.4, and wherein the hKd and the cKd are about 1 nM to about 5 nM.

[0123] 24. The single domain serum albumin binding protein of any one of embodiments 1-22, wherein the protein comprises the amino acid sequence as shown in SEQ ID NO.5, and wherein the hKd and the cKd are about 1 nM to about 5 nM.

[0124] 25. The single domain serum albumin binding protein of any one of embodiments 1-22, wherein the protein comprises the amino acid sequence as shown in SEQ ID NO.6, and wherein the hKd and the cKd are about 1 nM to about 5 nM.

[0125] 26. The single domain serum albumin binding protein of any one of embodiments 1-22, wherein the protein comprises the amino acid sequence as shown in SEQ ID NO.7, and wherein the hKd and the cKd are about 1 nM to about 5 nM.

[0126] 27. The single domain serum albumin binding protein of any one of embodiments 1-22, wherein the protein comprises the amino acid sequence as shown in SEQ ID NO. 8, and wherein the hKd and the cKd are about 5 nM to about 10 nM.

[0127] 28. The single domain serum albumin binding protein of any one of embodiments 1-22, wherein the protein comprises the amino acid sequence as shown in SEQ ID NO.9, and wherein the hKd and the cKd are about 1 nM to about 5 nM.

[0128] 29. The single-domain serum albumin binding protein of any one of embodiments 1-22, wherein the protein comprises the amino acid sequence shown in SEQ ID NO. 25, and wherein the hKd and the cKd are about 1 nM to about 5 nM.

[0129] 30. The single domain serum albumin binding protein of any one of embodiments 1-22, wherein the protein comprises the amino acid sequence as shown in SEQ ID NO. 26, and wherein the hKd and the cKd are about 1 nM to about 5 nM.

[0130] 31. The single domain serum albumin binding protein of any one of embodiments 1-22, wherein the protein comprises the amino acid sequence as shown in SEQ ID NO. 27, and wherein the hKd and the cKd are about 1 nM to about 5 nM.

[0131] 32. The single domain serum albumin binding protein of any one of embodiments 1-31, wherein the protein has an elimination half-life of at least 12 hours, at least 20 hours, at least 25 hours, at least 30 hours, at least 35 hours, at least 40 hours, at least 45 hours, at least 50 hours, or at least 100 hours.

[0132] 33. A single domain serum albumin binding protein comprising CDR1, CDR2 and CDR3, comprising the sequence as shown in SEQ ID NO.10 (wild type anti-HSA), wherein one or more amino acid residues selected from amino acid positions 28, 29, 30 or 31 of CDR1, positions 56, 57, 62 or 64 of CDR2, and positions 103 and 104 of CDR3 are substituted, wherein

[0133] Amino acid position 28 is substituted with arginine, lysine, serine or proline,

[0134] Amino acid position 29 is replaced by tyrosine,

[0135] Amino acid position 30 is substituted with arginine or lysine,

[0136] Amino acid position 31 is substituted with lysine, arginine or alanine,

[0137] Amino acid position 56 is substituted with arginine, threonine or alanine,

[0138] Amino acid position 57 is substituted with histidine, valine or threonine,

[0139] Amino acid position 62 is substituted with histidine, arginine, glutamic acid or serine,

[0140] Amino acid position 64 is substituted with leucine,

[0141] Amino acid position 103 is substituted with arginine, threonine or lysine,

[0142] Amino acid position 104 is substituted with lysine, valine, proline or asparagine.

[0143] 34. A single domain serum albumin binding protein as described in embodiment 33, which comprises one or more additional substitutions at amino acid positions other than positions 28, 29, 30, 31, 56, 57, 62, 64, 103 and 104.

[0144] 35. A single domain serum albumin binding protein as described in embodiment 33 or 34, comprising a substitution at position 29.

[0145] 36. A single domain serum albumin binding protein as described in embodiment 33 or 34, which comprises a substitution at position 31.

[0146] 37. A single domain serum albumin binding protein as described in embodiment 33 or 34, which comprises a substitution at position 56.

[0147] 38. A single domain serum albumin binding protein as described in embodiment 33 or 34, comprising a substitution at position 62.

[0148] 39. A single domain serum albumin binding protein as described in embodiment 33 or 34, comprising a substitution at position 64.

[0149] 40. A single domain serum albumin binding protein as described in embodiment 33 or 34, comprising a substitution at position 104.

[0150] 41. A single domain serum albumin binding protein as described in embodiment 33 or 34, which comprises substitutions at amino acid positions 31 and 62.

[0151] 42. A single domain serum albumin binding protein as described in embodiment 36, wherein amino acid position 31 is replaced by arginine.

[0152] 43. The single domain serum albumin binding protein of embodiment 41, wherein amino acid position 31 is substituted with arginine and amino acid position 62 is substituted with glutamic acid.

[0153] 44. A single domain serum albumin binding protein as described in embodiment 33 or 34, which comprises substitutions at amino acid positions 31, 56, 64 and 104.

[0154] 45. The single domain serum albumin binding protein of embodiment 44, wherein amino acid position 31 is substituted with lysine, amino acid position 56 is substituted with alanine, amino acid position 64 is substituted with leucine, and amino acid position 104 is substituted with lysine.

[0155] 46. ​​A single domain serum albumin binding protein as described in embodiment 33 or 34, wherein amino acid positions 29 and 104 are substituted.

[0156] 47. A single domain serum albumin binding protein as described in embodiment 46, wherein amino acid position 29 is replaced by tyrosine and amino acid position 104 is replaced by lysine.

[0157] 48. A single domain serum albumin binding protein as described in embodiment 33 or 34, wherein amino acid positions 31 and 56 are substituted.

[0158] 49. The single domain serum albumin binding protein of embodiment 48, wherein amino acid position 31 is substituted with lysine and amino acid position 56 is substituted with threonine.

[0159] 50. A single domain serum albumin binding protein as described in embodiment 33 or 34, wherein amino acid positions 31, 56 and 62 are substituted.

[0160] 51. The single domain serum albumin binding protein of embodiment 50, wherein amino acid position 31 is substituted with lysine, amino acid position 56 is substituted with threonine, and amino acid position 62 is substituted with glutamic acid.

[0161] 52. A single domain serum albumin binding protein as described in embodiment 33 or 34, wherein amino acid positions 31 and 104 are substituted.

[0162] 53. A single domain serum albumin binding protein as described in embodiment 52, wherein amino acid position 31 is replaced by arginine and amino acid position 104 is replaced by lysine.

[0163] 54. A single domain serum albumin binding protein as described in embodiment 33 or 34, wherein amino acid positions 31, 56 and 104 are substituted.

[0164] 55. The single domain serum albumin binding protein of embodiment 54, wherein amino acid position 31 is substituted with lysine, amino acid position 56 is substituted with arginine, and amino acid position 104 is substituted with valine.

[0165] 56. A single domain serum albumin binding protein as described in embodiment 33 or 34, wherein amino acid positions 31, 56, 62 and 104 are substituted.

[0166] 57. A single domain serum albumin binding protein as described in embodiment 56, wherein amino acid position 31 is substituted with lysine, amino acid position 56 is substituted with arginine, amino acid position 62 is substituted with glutamic acid, and amino acid position 104 is substituted with valine.

[0167] 58. A single domain serum albumin binding protein as described in any of embodiments 33-57, wherein the protein binds to human serum albumin and cynomolgus monkey serum albumin with comparable binding affinity (Kd).

[0168] 59. A single-domain serum albumin binding protein as described in any of embodiments 33-58, wherein the binding affinity (Kd) of the protein to mouse serum albumin is about 1.5 times to about 20 times weaker than the binding affinity (Kd) of the protein to human and cynomolgus monkey serum albumin.

[0169] 60. A single domain serum albumin binding protein as described in any of embodiments 33-59, wherein the protein binds to human serum albumin with a human Kd (hKd) of about 1 nM to about 100 nM, and binds to cynomolgus monkey serum albumin with a cynomolgus monkey Kd (cKd) of 1 nM to 100 nM.

[0170] 61. The single domain serum albumin binding protein of embodiments 33-60, wherein the hKd and the cKd are between 1 nM and about 5 nM or between about 5 nM and about 10 nM.

[0171] 62. The single domain serum albumin binding protein of any one of embodiments 33-61, wherein the hKd and the cKd are about 1 nM to about 2 nM, about 2 nM to about 3 nM, about 3 nM to about 4 nM, about 4 nM to about 5 nM, about 5 nM to about 6 nM, about 6 nM to about 7 nM, about 7 nM to about 8 nM, about 8 nM to about 9 nM, or about 9 nM to about 10 nM.

[0172] 63. A single domain serum albumin binding protein as described in any of embodiments 33-62, wherein the protein binds to human serum albumin with a human Kd (hKd) and binds to cynomolgus monkey serum albumin with a cynomolgus monkey Kd (cKd), and wherein the ratio of hKd to cKd (hKd:cKd) is 20:1 to 1:2.

[0173] 64. The single domain serum albumin binding protein of any one of embodiments 33-63, wherein amino acid position 31 is substituted with arginine, and wherein said hKd and said cKd are between about 1 nM and about 5 nM.

[0174] 65. The single domain serum albumin binding protein of any one of embodiments 33-63, wherein amino acid position 31 is substituted with arginine and amino acid position 62 is substituted with glutamic acid, and wherein the hKd and the cKd are between about 1 nM and about 5 nM.

[0175] 66. A single domain serum albumin binding protein as described in any of embodiments 33-63, wherein amino acid position 31 is substituted with lysine, amino acid position 56 is substituted with alanine, amino acid position 64 is substituted with leucine, and amino acid position 104 is substituted with lysine, and wherein the hKd and the cKd are about 1 nM to about 5 nM.

[0176] 67. A single domain serum albumin binding protein as described in any of embodiments 33-63, wherein amino acid position 29 is substituted with tyrosine, amino acid position 104 is substituted with lysine, and wherein the hKd and the cKd are about 1 nM to about 5 nM.

[0177] 68. The single domain serum albumin binding protein of any one of embodiments 33-63, wherein amino acid position 31 is substituted with lysine, amino acid position 56 is substituted with threonine, and wherein the hKd and the cKd are between about 1 nM and about 5 nM.

[0178] 69. The single domain serum albumin binding protein of any one of embodiments 33-63, wherein amino acid position 31 is substituted with lysine, amino acid position 56 is substituted with threonine, amino acid position 62 is substituted with glutamic acid, and wherein the hKd and the cKd are between about 1 nM and about 5 nM.

[0179] 70. The single domain serum albumin binding protein of any one of embodiments 33-63, wherein amino acid position 31 is substituted with arginine, amino acid position 104 is substituted with lysine, and wherein the hKd and the cKd are between about 5 nM and about 10 nM.

[0180] 71. A single domain serum albumin binding protein as described in any of embodiments 33-63, wherein amino acid position 31 is substituted with lysine, amino acid position 56 is substituted with arginine, amino acid position 104 is substituted with valine, and wherein the hKd and the cKd are about 1 nM to about 5 nM.

[0181] 72. A single domain serum albumin binding protein as described in any of embodiments 33-63, wherein amino acid position 31 is substituted with lysine, amino acid position 56 is substituted with arginine, amino acid position 62 is substituted with glutamic acid, and amino acid position 104 is substituted with valine, and wherein the hKd and the cKd are about 1 nM to about 5 nM.

[0182] 73. A single domain serum albumin binding protein as described in any of embodiments 33-72, wherein the protein has an elimination half-life of at least 12 hours, at least 20 hours, at least 25 hours, at least 30 hours, at least 35 hours, at least 40 hours, at least 45 hours, at least 50 hours or at least 100 hours.

[0183] 74. A single domain serum albumin binding protein comprising at least one mutation in CDR1, CDR2 or CDR3, wherein CDR1 has the sequence as shown in SEQ ID NO:11, CDR2 has the sequence as shown in SEQ ID NO:12, CDR3 has the sequence as shown in SEQ ID NO.13, and wherein the at least one mutation is not at amino acid position 1, 2, 7, 8, 9 or 10 of SEQ ID NO:11, position 1, 3, 6, 10 or 11 of SEQ ID NO:12, or position 1 or 2 of SEQ ID NO:13.

[0184] 75. A single domain serum albumin binding protein as described in embodiment 74, which comprises at least one mutation at an amino acid position selected from positions 3, 4, 5 and 6 of CDR1 (SEQ ID NO: 11), amino acid positions 7, 8, 13 and 15 of CDR2 (SEQ ID NO: 12), and amino acid positions 5 and 6 of CDR3 (SEQ ID NO: 13).

[0185] 76. A single domain serum albumin binding protein as described in embodiment 75, which comprises one or more additional substitutions at amino acid positions other than amino acid positions 3, 4, 5 and 6 of CDR1 (SEQ ID NO: 11), amino acid positions 7, 8, 13 and 15 of CDR2 (SEQ ID NO: 12), and amino acid positions 5 and 6 of CDR3 (SEQ ID NO: 13).

[0186] 77. The single domain serum albumin binding protein of any one of embodiments 74-76, comprising a mutation at amino acid position 6 of CDR1 (SEQ ID NO: 11).

[0187] 78. The single domain serum albumin binding protein of any one of embodiments 74-76, comprising mutations at amino acid position 6 of CDR1 (SEQ ID NO: 11) and amino acid position 13 of CDR2 (SEQ ID NO: 12).

[0188] 79. A single domain serum albumin binding protein as described in any of embodiments 74-76, which comprises mutations at amino acid position 6 of CDR1 (SEQ ID NO: 11), amino acid positions 7 and 15 of CDR2 (SEQ ID NO: 12), and amino acid position 6 of CDR3 (SEQID NO: 13).

[0189] 80. The single domain serum albumin binding protein of any one of embodiments 74-76, comprising a mutation at amino acid position 4 of CDR1 (SEQ ID NO: 11) and amino acid position 6 of CDR3 (SEQ ID NO: 13).

[0190] 81. The single domain serum albumin binding protein of any one of embodiments 74-76, comprising mutations at amino acid position 6 of CDR1 (SEQ ID NO: 11) and amino acid position 7 of CDR2 (SEQ ID NO: 12).

[0191] 82. A single domain serum albumin binding protein as described in any of embodiments 74-76, which comprises mutations at amino acid position 6 of CDR1 (SEQ ID NO: 11) and amino acid positions 7 and 13 of CDR2 (SEQ ID NO: 12).

[0192] 83. The single domain serum albumin binding protein of any one of embodiments 74-76, comprising a mutation at amino acid position 6 of CDR1 (SEQ ID NO: 11) and amino acid position 6 of CDR3 (SEQ ID NO: 13).

[0193] 84. A single domain serum albumin binding protein as described in any of embodiments 74-76, which comprises mutations at amino acid position 6 of CDR1 (SEQ ID NO: 11), amino acid position 7 of CDR2 (SEQ ID NO: 12), and amino acid position 6 of CDR3 (SEQ ID NO: 13).

[0194] 85. A single domain serum albumin binding protein as described in any of embodiments 74-76, which comprises mutations at amino acid position 6 of CDR1 (SEQ ID NO: 11), amino acid positions 7 and 13 of CDR2 (SEQ ID NO: 12), and amino acid position 6 of CDR3 (SEQID NO: 13).

[0195] 86. A single domain serum albumin binding protein as described in any of embodiments 74-85, wherein the protein binds to human serum albumin and cynomolgus monkey serum albumin with comparable binding affinity (Kd).

[0196] 87. A single-domain serum albumin binding protein as described in any of embodiments 74-86, wherein the binding affinity (Kd) of the protein to mouse serum albumin is about 1.5 times to about 20 times weaker than the binding affinity (Kd) of the protein to human and cynomolgus monkey serum albumin.

[0197] 88. A single domain serum albumin binding protein as described in any of embodiments 74-87, wherein the protein binds to human serum albumin with a human Kd (hKd) of about 1 nM to about 100 nM, and binds to cynomolgus monkey serum albumin with a cynomolgus monkey Kd (cKd) of 1 nM to 100 nM.

[0198] 89. The single domain serum albumin binding protein of any one of embodiments 74-88, wherein the hKd and the cKd are from 1 nM to about 5 nM or from about 5 nM to about 10 nM.

[0199] 90. A single domain serum albumin binding protein as described in any of embodiments 74-89, wherein the hKd and the cKd are about 1 nM to about 2 nM, about 2 nM to about 3 nM, about 3 nM to about 4 nM, about 4 nM to about 5 nM, about 5 nM to about 6 nM, about 6 nM to about 7 nM, about 7 nM to about 8 nM, about 8 nM to about 9 nM or about 9 nM to about 10 nM.

[0200] 91. A single domain serum albumin binding protein as described in any of embodiments 74-90, wherein the protein binds to human serum albumin with a human Kd (hKd) and binds to cynomolgus monkey serum albumin with a cynomolgus monkey Kd (cKd), and wherein the ratio of hKd to cKd (hKd:cKd) is 20:1 to 1:2.

[0201] 92. A single domain serum albumin binding protein as described in any of embodiments 74-91, wherein amino acid position 6 of CDR1 (SEQ ID NO: 11) is mutated to arginine, and wherein the hKd and the cKd are about 1 nM to about 5 nM.

[0202] 93. A single domain serum albumin binding protein as described in any of embodiments 74-91, wherein amino acid position 6 of CDR1 (SEQ ID NO:11) is mutated to arginine, and amino acid position 13 of CDR2 (SEQ ID NO:12) is mutated to glutamic acid, and wherein the hKd and the cKd are about 1 nM to about 5 nM.

[0203] 94. A single domain serum albumin binding protein as described in any of embodiments 74-91, wherein amino acid position 6 of CDR1 (SEQ ID NO:11) is mutated to lysine, amino acid positions 7 and 15 of CDR2 (SEQ ID NO:12) are mutated to alanine and leucine, respectively, and amino acid position 6 of CDR3 (SEQ ID NO:13) is mutated to lysine, and wherein the hKd and the cKd are about 1 nM to about 5 nM.

[0204] 95. A single domain serum albumin binding protein as described in any of embodiments 74-91, wherein amino acid position 4 of CDR1 (SEQ ID NO:11) is mutated to tyrosine, and amino acid position 6 of CDR3 (SEQ ID NO:13) is mutated to lysine, and wherein the hKd and the cKd are about 1 nM to about 5 nM.

[0205] 96. A single domain serum albumin binding protein as described in any of embodiments 74-91, wherein amino acid position 6 of CDR1 (SEQ ID NO:11) is mutated to lysine, amino acid position 7 of CDR2 (SEQ ID NO:12) is mutated to threonine, and wherein the hKd and the cKd are about 1 nM to about 5 nM.

[0206] 97. A single domain serum albumin binding protein as described in any of embodiments 74-91, wherein amino acid position 6 of CDR1 (SEQ ID NO:11) is mutated to lysine, and amino acid positions 7 and 13 of CDR2 (SEQ ID NO:12) are mutated to threonine and glutamate, respectively, and wherein the hKd and the cKd are about 1 nM to about 5 nM.

[0207] 98. A single domain serum albumin binding protein as described in any of embodiments 74-91, wherein the amino acid position 6 of CDR1 (SEQ ID NO:11) is mutated to arginine, the amino acid position 6 of CDR3 (SEQ ID NO:12) is mutated to lysine, and wherein the hKd and the cKd are about 5nM to about 10nM.

[0208] 99. A single domain serum albumin binding protein as described in any of embodiments 74-91, wherein amino acid position 6 of CDR1 (SEQ ID NO:11) is mutated to lysine, amino acid position 7 of CDR2 (SEQ ID NO:12) is mutated to arginine, amino acid position 6 of CDR3 (SEQ ID NO:13) is mutated to valine, and wherein the hKd and the cKd are about 1 nM to about 5 nM.

[0209] 100. A single domain serum albumin binding protein as described in any of embodiments 74-91, wherein amino acid position 6 of CDR1 (SEQ ID NO:11) is mutated to lysine, amino acid positions 7 and 13 of CDR2 (SEQ ID NO:12) are mutated to arginine and glutamic acid, respectively, and amino acid position 6 of CDR3 (SEQ ID NO:13) is mutated to valine, and wherein the hKd and the cKd are about 1 nM to about 5 nM.

[0210] 101. The single domain serum albumin binding protein of any of embodiments 74-100, wherein the protein has an elimination half-life of at least 12 hours, at least 20 hours, at least 25 hours, at least 30 hours, at least 35 hours, at least 40 hours, at least 45 hours, at least 50 hours, or at least 100 hours.

[0211] 102. A polynucleotide encoding a single domain serum albumin binding protein according to any one of embodiments 1-101.

[0212] 103. A vector comprising the polynucleotide as described in embodiment 102.

[0213] 104. A host cell transformed with the vector according to embodiment 103.

[0214] 105. A pharmaceutical composition comprising (i) a single domain serum albumin binding protein according to any one of embodiments 1-101, a polynucleotide according to embodiment 102, a vector according to embodiment 103 or a host cell according to embodiment 104, and (ii) a pharmaceutically acceptable carrier.

[0215] 106. A method for producing a single-domain serum albumin binding protein according to any one of embodiments 1-101, the method comprising culturing a host transformed or transfected with a vector comprising a nucleic acid sequence encoding the single-domain serum albumin binding protein according to any one of embodiments 1-101 under conditions allowing expression of the serum albumin binding protein, and recovering and purifying the produced protein from the culture.

[0216] 107. A method for treating or ameliorating a proliferative disease, a neoplastic disease, an inflammatory disease, an immune disorder, an autoimmune disease, an infectious disease, a viral disease, an allergic reaction, a parasitic reaction, a graft-versus-host disease, or a host-versus-graft disease, comprising administering to a subject in need thereof a single-domain serum albumin binding protein according to any one of embodiments 1-101.

[0217] 108. A method according to embodiment 107, wherein the subject is human.

[0218] 109. The method of embodiment 108, wherein the method further comprises administering an agent in conjunction with the single domain serum albumin binding protein of any one of embodiments 1-100.

[0219] 110. A multispecific binding protein comprising a single domain serum albumin binding protein according to any one of embodiments 1, embodiment 33 or embodiment 74.

[0220] 111. An antibody comprising the single domain serum albumin binding protein of embodiment 1, embodiment 33 or embodiment 74.

[0221] 112. A multispecific antibody, bispecific antibody, sdAb, heavy chain variable domain, peptide or ligand comprising a single domain serum albumin binding protein according to embodiment 1, embodiment 33 or embodiment 74.

[0222] 113. An antibody comprising a single domain serum albumin binding protein according to embodiment 1, embodiment 33 or embodiment 74, wherein the antibody is a single domain antibody.

[0223] 114. A single domain antibody as described in embodiment 113, wherein the antibody is derived from the heavy chain variable region of IgG.

[0224] 115. A multispecific binding protein or antibody comprising a single domain serum albumin binding protein according to any one of embodiments 1, embodiment 33 or embodiment 74 and a CD3 binding domain.

[0225] 116. A method for treating or ameliorating a proliferative disease, a tumor disease, an inflammatory disease, an immune disorder, an autoimmune disease, an infectious disease, a viral disease, an allergic reaction, a parasitic reaction, a graft-versus-host disease, or a host-versus-graft disease, comprising administering to a subject in need thereof a multispecific antibody according to any one of embodiments 111-115.

[0226] 117. A single-domain serum albumin binding protein as described in any of embodiments 1-101, wherein the protein comprises the amino acid sequence shown in SEQ ID NO.4.

[0227] 118. A single-domain serum albumin binding protein as described in any of embodiments 1-101, wherein the protein comprises the amino acid sequence shown in SEQ ID NO.7.

[0228] 119. A single-domain serum albumin binding protein as described in any of embodiments 1-101, wherein the protein comprises the amino acid sequence shown in SEQ ID NO.9.

[0229] 120. A single-domain serum albumin binding protein as described in any of embodiments 1-101, wherein the protein comprises the amino acid sequence shown in SEQ ID NO.26.

[0230] 121. A single-domain serum albumin binding protein as described in any of embodiments 1-101, wherein the protein comprises the amino acid sequence shown in SEQ ID NO.27.

[0231] 122. A single-domain serum albumin binding protein as described in any of embodiments 1-101, wherein the protein comprises the amino acid sequence shown in SEQ ID NO.5.

[0232] 123. A single-domain serum albumin binding protein as described in any of embodiments 1-101, wherein the protein comprises the amino acid sequence shown in SEQ ID NO.6.

[0233] 124. A single-domain serum albumin binding protein as described in any of embodiments 1-101, wherein the protein comprises the amino acid sequence shown in SEQ ID NO.8.

[0234] 125. A single-domain serum albumin binding protein as described in any of embodiments 1-101, wherein the protein comprises the amino acid sequence shown in SEQ ID NO.25.

[0235] Example

[0236] Example 1: Anti-HSA single domain antibodies with equivalent binding properties to the parent anti-HSA single domain antibody Generation of variants

[0237] Characterization of parental anti-HSA phage

[0238] CD3 was used as a negative control to determine the specific binding of the parental anti-HSA phage to the HSA antigen ( Figure 1 ), and the cross-reactivity of anti-HSA phage with human, cynomolgus monkey, and mouse serum albumin was determined ( Figure 2 ).

[0239] Single displacement HSA sdAb phage library

[0240] Single substitution libraries were provided for each of the three CDR domains. The single substitution libraries were bound to HSA and then washed in buffer containing various levels of HSA. Phage bound at 0 and 24 hours were obtained and counted. Phage selected by washing with 2.5 mg / ml HSA in buffer for 24 hours were used to generate two independent combinatorial phage libraries.

[0241] Combinatorial anti-HSA library

[0242] MSA was used as the selection target in the first round. After the combined phages from two independent libraries were bound, the wells were washed for 24 hours. HSA was used as the selection target in the second round. After the two libraries were bound, the wells were washed in 1 mg / ml HSA for 24 hours. The insert obtained from the second round of selection by PCR was subcloned into the ME10 His6 expression vector (6XHis sequence is disclosed as SEQ ID NO:38). 96 clones were picked, and the DNA was purified, sequenced and transfected into Expi293 cells.

[0243] Binding affinity determination

[0244] The supernatants were used to estimate the Kd for HSA and CSA using the Octet platform. Nine clones were selected for further characterization based on binding affinity compared to the parental sdAb and robust production, aggregation and stability properties ( Figure 3 ).

[0245] Example 2: Pharmacokinetics of trispecific antibodies comprising an anti-HSA single domain antibody

[0246] A trispecific antibody was prepared using the anti-HSA single domain antibody of Example 1, and the elimination half-life of the trispecific antibody was evaluated in animal studies.

[0247] The trispecific antibody was administered intramuscularly to cynomolgus monkeys at 0.5 mg / kg bolus. Another group of cynomolgus monkeys received a protein of comparable size having CD3 and CD20 binding domains but lacking the HSA binding domain. The third and fourth groups received an antibody having CD3 and HSA binding domains and a protein having CD20 and HSA binding domains, respectively, and both were of comparable size to the trispecific antibody. Each test group consisted of 5 monkeys. Serum samples were taken at designated time points, serially diluted, and the concentration of the protein was determined using a binding ELISA to CD3 and / or CD20.

[0248] Pharmacokinetic analysis was performed using test article plasma concentrations. Group mean plasma data for each test article fit a multi-exponential curve when plotted against time after administration. These data were fit to a standard two-compartment model using bolus input and first-order rate constants for the distribution and elimination phases. The general equation for the best fit for data administered intravenously was: c(t) = Ae -αt +Be -βt , where c(t) is the plasma concentration at time t, A and B are intercepts on the Y axis, and α and β are the apparent first-order rate constants for the distribution and elimination phases, respectively. The α phase is the initial phase of clearance and reflects the distribution of the protein to all extracellular fluids of the animal, while the second or β phase portion of the decay curve represents the true plasma clearance. Methods for fitting such equations are well known in the art. For example, A = D / V(α-k21) / (α-β), B = D / V(β-k21) / (α-β), and α and β (for α>β) are quadratic equations r 2 +(k12+k21+k10)r+k21k10=root of 0, using the following estimated parameters: V=volume of distribution, k10=elimination rate, k12=transfer rate from compartment 1 to compartment 2, k21=transfer rate from compartment 2 to compartment 1, and D=administered dose.

[0249] Data Analysis: Using KaleidaGraph TM V.3.09Copyright 1986-1997.Synergy Software.Reading,Pa.) to generate concentration versus time curves. Values ​​reported as less than the reportable value (LTR) were not included in the PK analysis and are not represented graphically. WinNonlin software ( Professional V.3.1 WinNonlin TMCopyright 1998-1999. Pharsight Corporation. Mountain View, Calif.) Pharmacokinetic parameters were determined by compartmental analysis. Pharmacokinetic parameters were calculated as described in Ritschel WA and Kearns GL, 1999, IN: Handbook Of Basic Pharmacokinetics Including Clinical Applications, 5th Edition, American Pharmaceutical Assoc., Washington, DC.

[0250] The trispecific antibodies comprising the anti-HSA single domain antibodies of Example 1 are expected to have improved pharmacokinetic parameters, such as increased elimination half-life, compared to proteins lacking the HSA binding domain.

[0251] Example 3: Thermal stability of anti-HSA single domain antibody variants

[0252] The hydrophobic exposure temperature (T h ) corresponds to the derivative of the inflection point of peak dye fluorescence and is known to be related to the melting temperature (T m The aim of this study was to evaluate the T h .

[0253] Protein production

[0254] The sequence of the anti-huALB single domain antibody was cloned into pcDNA3.4 (Invitrogen) with a leader sequence in front and a 6x histidine tag (SEQ ID NO: 38) in the back. Expi293F cells (Life Technologies A14527) were suspended and maintained in optimal growth bottles (Optimum Growth Flasks) (Thomson) at a density of 0.2-8x 1e6 cells / ml in Expi 293 culture medium. Purified plasmid DNA was transfected into Expi293F cells according to the Expi293 expression system kit (Life Technologies, A14635) protocol and maintained for 4-6 days after transfection. Conditioned culture medium was partially purified by affinity chromatography and desalting chromatography. Anti-huCD3e scFv protein was concentrated with an Amicon Ultra centrifugal filter unit (EMD Millipore), applied to a Superdex 200 size exclusion medium (GE Healthcare) and dissolved in a neutral buffer containing excipients. Fraction pooling and final purity were assessed by SDS-PAGE and analytical size exclusion chromatography (SEC).The absorbance of purified protein solutions was measured at 280 nm using SpectraMax M2 (Molecular Devices) and UV-transparent 96-well plates (Corning 3635), and their concentrations were calculated from the molar extinction coefficients.

[0255] Differential Scanning Fluorescence

[0256] Purified anti-HSA single domain antibody protein was diluted to 0.2 to 0.25 mg / ml and placed in MicroAmp EnduraPlate optical microplates and adhesive films (Applied Biosystems 4483485 and 4311971) along with 5x SYPRO orange dye (Life Technologies S6651) at a final concentration of 0.15% DMSO in a neutral buffer containing excipients. The plate containing the diluted protein and dye mixture was loaded into an ABI 7500 fast real-time PCR instrument (Applied Biosytems) and subjected to a multi-step thermal gradient from 25° C. to 95° C. The thermal gradient included a two-minute hold at each degree Celsius, excitation at 500 nm and collection of emission with a ROX filter. Figure 4 The purified anti-HSA single domain antibody protein is presented in T h (in degrees Celsius).

[0257] Example 4: Relative propensity of anti-HSA single domain antibody variants to dimerize when exposed to low pH

[0258] Anti-HSA single domain antibody proteins were expressed in Expi293-F cells as described above. Conditioned medium of each variant was applied to protein A agarose (GE Healthcare, 17519901) packed in a column, washed extensively with TRIS buffered saline, eluted with 0.05% (vol / vol) acetic acid at pH 3, kept at room temperature for up to 10 minutes, then partially neutralized to pH 5, and subsequently desalted into a neutral buffer containing excipients using a Sephadex G25 column (GE Healthcare 17058401).

[0259] The concentration of the purified anti-HSA single domain antibody variants was determined by absorbance at 280 nm as described in Example 3. The purified proteins were evaluated by SDS-PAGE and analytical SEC performed on a 1200 LC with Chemstation software (Agilent) using a Yarra 2000 SEC column (Phenomenex 00H-4512-E0) in phosphate buffer containing solvent. The peaks corresponding to dimers and monomers were manually integrated and the values ​​are presented in Figure 5 middle.

[0260]

[0261]

[0262]

Claims

1. A single domain serum albumin binding protein comprising the amino acid sequence of SEQ ID NO.

9.

2. The single domain serum albumin binding protein of claim 1, wherein the binding affinity (Kd) of the protein to mouse serum albumin is about 1.5 to about 20 times weaker than the binding affinity (Kd) of the protein to human and cynomolgus monkey serum albumin.

3. The single domain serum albumin binding protein of claim 2, wherein the protein binds to human serum albumin with a human Kd (hKd) and binds to cynomolgus monkey serum albumin with a cynomolgus monkey Kd (cKd), wherein the ratio between hKd and cKd (hKd:cKd) ranges from about 20:1 to about 1:

2.

4. The single domain serum albumin binding protein of claim 1, wherein the protein has an elimination half-life of at least 12 hours, at least 20 hours, at least 25 hours, at least 30 hours, at least 35 hours, at least 40 hours, at least 45 hours, at least 50 hours, or at least 100 hours.

5. A single domain serum albumin binding protein comprising the amino acid sequence of SEQ ID NO.

10.

6. The single domain serum albumin binding protein of claim 5, wherein the binding affinity (Kd) of the protein to mouse serum albumin is about 1.5-fold to about 20-fold weaker than the binding affinity (Kd) of the protein to human and cynomolgus monkey serum albumin.

7. The single domain serum albumin binding protein of claim 6, wherein the protein binds to human serum albumin with a human Kd (hKd), binds to cynomolgus monkey serum albumin with a cynomolgus monkey Kd (cKd), and binds to cynomolgus monkey serum albumin, wherein the ratio between hKd and cKd (hKd:cKd) ranges from about 20:1 to about 1:

2.

8. The serum albumin binding protein domain of claim 5, wherein the protein has an elimination half-life of at least 12 hours, at least 20 hours, at least 25 hours, at least 30 hours, at least 35 hours, at least 40 hours, at least 45 hours, at least 50 hours, or at least 100 hours.

9. A polynucleotide encoding a single domain serum albumin binding protein according to any one of claims 1 to 8.

10. A polynucleotide encoding the single domain serum albumin binding protein according to claim 1.

11. A vector comprising the polynucleotide according to claim 9.

12. A vector comprising the polynucleotide according to claim 10.

13. A host cell comprising the polynucleotide according to claim 9.

14. A host cell comprising the polynucleotide according to claim 10.

15. A host cell comprising the vector according to claim 11.

16. A host cell comprising the vector according to claim 12.

17. Use of the single domain serum albumin binding protein according to any one of claims 1 to 8 in the preparation of a medicament for treating or ameliorating proliferative diseases, tumor diseases, inflammatory diseases, immune disorders, autoimmune diseases, infectious diseases, viral diseases, allergies, parasitic reactions, graft versus host disease or host versus graft disease.

18. Use of the single-domain serum albumin binding protein according to claim 1 in the preparation of a medicament for treating or ameliorating proliferative diseases, tumor diseases, inflammatory diseases, immune disorders, autoimmune diseases, infectious diseases, viral diseases, allergies, parasitic reactions, graft-versus-host disease or host-versus-graft disease.

19. A multispecific binding protein comprising the single domain serum albumin binding protein according to any one of claims 1 to 8.

20. A multispecific binding protein comprising the single domain serum albumin binding protein of claim 1.

21. A single domain serum albumin binding protein comprising complementarity determining regions CDR1, CDR2 and CDR3, wherein (a) the amino acid sequence of CDR1 is shown as GFX1X2X3X4FGMS (SEQ ID NO. 1), X1 is threonine, arginine, lysine, serine or proline, X2 is phenylalanine or tyrosine, X3 is serine, arginine or lysine, and X4 is serine, lysine, arginine or alanine; (b) the amino acid sequence of CDR2 is as shown in SISGSGX5X6TLYAX7SX8K (SEQ ID NO. 2), X5 is serine, arginine, threonine or alanine, X6 is aspartic acid, histidine, valine or threonine, X7 is aspartic acid, histidine, arginine or serine, and X8 is valine or leucine; and (c) The amino acid sequence of CDR3 is GGSLX9X 10 (SEQ ID NO.3), X9 is serine, arginine, threonine or lysine, X 10 is arginine, lysine, valine, proline or asparagine, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9 and X 10Different from each other, they are threonine, phenylalanine, serine, serine, serine, aspartic acid, aspartic acid, aspartic acid, valine, serine and arginine respectively.

22. A single domain serum albumin binding protein comprising CDR1, CDR2 and CDR3, comprising the sequence shown in SEQ ID NO.10, wherein one or more amino acid residues selected from amino acid positions 28, 29, 30 or 31 of CDR1, positions 56, 57, 62 or 64 of CDR2, and positions 103 and 104 of CDR3 are substituted, wherein Amino acid position 28 is substituted with arginine, lysine, serine or proline, Amino acid position 29 is replaced by tyrosine, Amino acid position 30 is substituted with arginine or lysine, Amino acid position 31 is substituted with lysine, arginine or alanine, Amino acid position 56 is substituted with arginine, threonine or alanine, Amino acid position 57 is substituted with histidine, valine or threonine, Amino acid position 62 is substituted with histidine, arginine, glutamic acid or serine, Amino acid position 64 is substituted with leucine, Amino acid position 103 is substituted with arginine, threonine or lysine, Amino acid position 104 is substituted with lysine, valine, proline or asparagine.

23. A composition comprising a single domain serum albumin binding protein comprising complementarity determining regions CDR1, CDR2 and CDR3, wherein a. The amino acid sequence of CDR1 is shown in SEQ ID NO.15; b. The amino acid sequence of CDR2 is shown in SEQ ID NO.22; and c. The amino acid sequence of CDR3 is shown in SEQ ID NO.

24.

24. A multispecific protein comprising a serum albumin binding domain, a target antigen binding domain, and a domain that binds to a protein within a T cell receptor complex (TCR), wherein the serum albumin binding domain includes complementarity determining regions CDR1, CDR2, and CDR3, wherein (a) the amino acid sequence of CDR1 is shown as GFX1X2X3X4FGMS (SEQ ID NO. 1), X1 is threonine, arginine, lysine, serine or proline, X2 is phenylalanine or tyrosine, X3 is serine, arginine or lysine, and X4 is serine, lysine, arginine or alanine; (b) the amino acid sequence of CDR2 is as shown in SISGSGX5X6TLYAX7SX8K (SEQ ID NO. 2), X5 is serine, arginine, threonine or alanine, X6 is aspartic acid, histidine, valine or threonine, X7 is aspartic acid, histidine, arginine or serine, and X8 is valine or leucine; and (c) The amino acid sequence of CDR3 is GGSLX9X 10 (SEQ ID NO.3), X9 is serine, arginine, threonine or lysine, X 10 is arginine, lysine, valine, proline or asparagine, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9 and X 10 Different from each other, they are threonine, phenylalanine, serine, serine, serine, aspartic acid, aspartic acid, aspartic acid, valine, serine and arginine respectively.

25. A multispecific protein comprising a serum albumin binding domain, a target antigen binding domain, and a domain that binds to a protein within a T cell receptor complex (TCR), wherein the serum albumin binding domain comprises complementarity determining regions CDR1, CDR2, and CDR3 within the sequence as shown in SEQ ID NO.10, wherein one or more amino acid residues selected from amino acid positions 28, 29, 30, or 31 of CDR1; positions 56, 57, 62, or 64 of CDR2, and positions 103 and 104 of CDR3 are replaced, wherein Amino acid position 28 is substituted with arginine, lysine, serine or proline, Amino acid position 29 is replaced by tyrosine, Amino acid position 30 is substituted with arginine or lysine, Amino acid position 31 is substituted with lysine, arginine or alanine, Amino acid position 56 is substituted with arginine, threonine or alanine, Amino acid position 57 is substituted with histidine, valine or threonine, Amino acid position 62 is substituted with histidine, arginine, glutamic acid or serine, Amino acid position 64 is substituted with leucine, Amino acid position 103 is substituted with arginine, threonine or lysine, Amino acid position 104 is substituted with lysine, valine, proline or asparagine.

26. A multispecific protein comprising a serum albumin binding domain, a target antigen binding domain, and a domain that binds to a protein within a T cell receptor complex (TCR), wherein the serum albumin comprises at least one mutation in CDR1, CDR2, or CDR3, wherein CDR1 has a sequence as shown in SEQ ID NO.11, CDR2 has a sequence as shown in SEQ ID NO.12, and CDR3 has a sequence as shown in SEQ ID NO.13, wherein at least one mutation is not at amino acid position 1, 2, 7, 8, 9, or 10 of SEQ ID NO.11, position 1, 3, 6, 10, or 11 of SEQ ID NO.12, or position 1 or 2 of SEQ ID NO.13.